

Clinical and Genomic Evaluation of 207 Genetic Myopathies in the Indian Subcontinent

1 **Samya Chakravorty**^{1, 2, 3, 4, *}, **Babi Ramesh Reddy Nallamilli**⁵, **Satish Khadilkar**^{6, 7, 8},
2 **Madhubala Singla**^{6, 7, 8}, **Ashish Bhutada**⁶, **Rashna Dastur**⁹, **Pradnya Gaitonde**⁹, **Laura**
3 **Rufibach**¹⁰, **Logan Gloster**^{1, 4}, **Madhuri Hegde**^{4, 5, *}

4

5 ¹ Emory University Department of Pediatrics, Atlanta, GA, USA

6 ² Emory University Department of Human Genetics, Atlanta, GA, USA

7 ³ Division of Neurosciences, Children's Healthcare of Atlanta, GA, USA

8 ⁴ School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA

9 ⁵ PerkinElmer Genomics, Global Laboratory Services, Waltham, MA, USA.

10 ⁶ Department of Neurology, Bombay Hospital, Mumbai, Maharashtra, India

11 ⁷ Department of Neurology, Sir J J Group of Hospitals, Grant Medical College, Mumbai,
12 Maharashtra, India

13 ⁸ Bombay Hospital Institute of Medical Sciences, Mumbai, Maharashtra, India

14 ⁹ Centre for Advanced Molecular Diagnostics in Neuromuscular Disorders (CAMDND) Mumbai,
15 Maharashtra, India

16 ¹⁰ Jain Foundation, Seattle, WA, USA 98115

17

18

19 *** Correspondence:**

20

21 *Samya Chakravorty*

22 samya.chakravorty@emory.edu

23

24 *Madhuri Hegde*

25 madhuri.hegde@perkinelmer.com

26

27 **Lead Contact:** Samya Chakravorty (samya.chakravorty@emory.edu)

28

29 **Manuscript word count:** 5507, **Number of Figures:** 3, **Number of Tables:** 6

30

31 **Keywords:** Inherited Myopathies, LGMD, Exome Sequencing, Next Generation Sequencing,
32 Molecular Diagnostics, India

33

34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73

ABSTRACT

Objective

Inherited myopathies comprise more than 200 different individually rare disease-subtypes but when combined together have a high prevalence of 1 in 6000 individuals across the world. Our goal was to determine for the first time the clinical- and gene-variant spectrum of genetic myopathies in a substantial cohort study of the Indian subcontinent.

Methods

In this cohort-study, we performed the first large clinical exome sequencing (ES) study with phenotype correlation on 207 clinically well-characterized inherited myopathy-suspected patients from the Indian subcontinent with diverse ethnicities.

Results

Clinical-correlation driven definitive molecular diagnosis was established in 49% (101 cases; 95% CI, 42%-56%) of patients with the major contributing pathogenicity in either of three genes, *GNE* (28%; *GNE*-myopathy), *DYSF* (25%; Dysferlinopathy) and *CAPN3* (19%; Calpainopathy). We identified 65 variant alleles comprising 37 unique variants in these three major genes. 78% of the *DYSF* patients were homozygous for the detected pathogenic variant suggesting the need for carrier-testing for autosomal-recessive disorders like Dysferlinopathy that are common in India. We describe the observed clinical spectrum of myopathies including uncommon and rare subtypes in India: Sarcoglycanopathies (*SGCA/B/D/G*), Collagenopathy (*COL6A1/2/3*), Anoctaminopathy (*ANO5*), telethoninopathy (*TCAP*), Pompe-disease (*GAA*), Myoadenylate-deaminase-deficiency-myopathy (*AMPD1*), myotilinopathy (*MYOT*), laminopathy (*LMNA*), HSP40-proteinopathy (*DNAJB6*), Emery-Dreifuss-muscular-dystrophy (*EMD*), Filaminopathy (*FLNC*), TRIM32-proteinopathy (*TRIM32*), POMT1-proteinopathy (*POMT1*), and Merosin-deficiency-congenital-muscular-dystrophy-type-1 (*LAMA2*). 13 Patients harbored pathogenic variants in >1 gene and had unusual clinical features suggesting a possible role of synergistic-heterozygosity / digenic-contribution to disease presentation and progression.

Conclusions

Application of clinically-correlated ES to myopathy diagnosis has improved our understanding of the clinical and genetic spectrum of different subtypes and their overlaps in Indian patients. This, in turn, will enhance the global gene-variant-disease databases by including data from developing countries/continents for more efficient clinically-driven molecular diagnostics.

74

75

76 INTRODUCTION

77 To date, >250 genes are associated with various inherited neuromuscular disorders (NMDs) (1-4)
78 comprising a broad heterogeneous group of genetic myopathies. However, significant numbers of
79 affected patients remain without a definitive molecular diagnosis due to novel gene or multiple gene
80 associations with disease (5, 6). The autosomal-dominant forms represent <10% of all genetic
81 myopathies (6-8) and are usually associated with milder clinical-presentation and adult-onset.
82 Whereas, for the more common autosomal-recessive forms, multiple monogenic subtypes have been
83 identified including those that make up the limb-girdle muscular dystrophies (LGMDs) (5, 9).
84 Definitive molecular diagnosis is a prerequisite for patient participation in clinical-trials or precision
85 medicine treatment and management. Hence, it is important to understand the genetic etiologies and
86 subtype prevalence in different populations to enhance global variant databases for more efficient and
87 accurate gene-variant classification and diagnosis.

88 Several studies reported the use of next-generation-sequencing (NGS) for molecular diagnosis
89 in small/large genetic myopathy patient-cohorts in different countries (6, 10-12). But the application
90 of exome sequencing (ES) for a large cohort of myopathy patients from the Indian subcontinent has
91 not been reported previously. Similar to the rising awareness of the importance of African genomes
92 or exomes in global public health and enhancing public databases, it is important to study the
93 populations of the Indian subcontinent and Asia as a whole comprising of the largest proportion of
94 the world population which offers diverse ethnic and genetic backgrounds (13-16). Moreover, the
95 sociocultural belief systems and traditions have led to community marriages, consanguinity and intra-
96 communal exogamy in sections of the Indian population. Here, we performed the first large-scale ES
97 study on 207 clinically well-characterized inherited myopathy-suspected patients of diverse
98 ethnicities from the Indian subcontinent to identify the causative gene and disease-subtypes. Our
99 results yield interesting observations on Indian myopathy clinical and gene-variant landscape and
100 approaches to both clinical and genetic diagnosis in muscular dystrophy and myopathy in general.

101

102

103 MATERIALS AND METHODS

104

105 Standard Protocol Approvals, Registrations, and Patient Consents

106 Written, informed consent was obtained from all individuals or minors' parent or legal guardian or
107 next of kin for the publication of any potentially identifiable images or data included in this article.
108 Written informed consents were obtained from all participants of the study for all procedures
109 according to approved Ethics committee Institutional Review Board protocol. All participants
110 (including parents or legal guardians in case of minor patients) were provided pre- and post-test
111 routine genetic counseling.

112

113

114 **Patients and Study Design**

115 In an effort to understand the genetic basis of myopathies, over a 3-year period (2016-2019) a total of
116 207 patients with clinical suspicion of an inherited myopathy were recruited (see Questionnaires in
117 Supplementary Material) based on the following inclusion and exclusion criteria. Inclusion criteria:
118 Patients with a suspected clinical diagnosis of genetic myopathy. Exclusion Criteria: 1. Patients with
119 confirmed diagnosis of Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular
120 dystrophy (FSHD), myotonic dystrophy (DM1 and DM2), mitochondrial myopathy and Acquired
121 myopathies. DMD, myotonic dystrophies and FSHD were genetically diagnosed. Mitochondrial
122 myopathies were diagnosed based on muscle biopsy immunohistochemistry and/or genetic diagnosis.
123 We used modified Gomori trichrome, cytochrome oxidase (COX) and nicotinamide adenine
124 dinucleotide (NADH) stains for the demonstration of mitochondrial dysfunction, supported by
125 electron microscopy as needed. There was no age restriction and the patients were recruited from
126 across the Indian subcontinent at a single tertiary care hospital.

127

128

129 **Clinical Evaluation**

130 All patients underwent comprehensive clinical evaluation. Clinical details including age of onset,
131 initial symptoms, region in which weakness started first, and functional status of the patient was
132 collected whenever available for all patients recruited in the study. Pattern of weakness including upper
133 limbs or lower limbs, or both, proximal or distal or both, symmetrical or asymmetrical, and differential
134 weakness, was determined. Detailed pedigree analysis was performed. Available affected family
135 members were examined. Detailed history regarding the origins and ancestry and marriage customs
136 practiced in the specific ethnic community was documented. Patients underwent detailed clinical
137 examination with focus on the motor system. Hypertrophy, atrophy of muscles was determined from
138 inspection. Neck flexors, extensors and other total 16 pairs of muscles (trapezius, deltoid, serratus
139 anterior, biceps, brachioradialis, triceps, wrist flexors and extensors, ileopsoas, hip adductors,
140 abductors, extensors, quadriceps, hamstrings, tibialis anterior, gastrocnemius-soleus) were examined
141 as per the MRC grading system of 0 to 5. Small muscles of hands, feet, and paraspinal muscle were
142 also examined. Serum creatine kinase was determined at the time of presentation prior to
143 electromyography. Electromyography and nerve conduction studies were performed in all patients.
144 Electrocardiography was done in all patients and Echocardiography was done in selected symptomatic
145 patients.

146

147

148 **Muscle Biopsy Procedure**

149 Muscle biopsy procedure was performed for only the consenting patients as per routine methodology.
150 Muscle biopsy was performed from clinically affected muscle with power between MRC grades 3 to
151 4. Biopsy specimens were snap frozen in chilled isopentane for frozen sections and later taken in
152 formalin for paraffin embedding. Routine assessment of morphological changes was carried out on
153 frozen and paraffin sections. Biopsy specimens from those patients who consented for the procedure
154 were grouped into dystrophic, myopathic, dystrophic with inflammation, myositis, mixed

155 (neurogenic and myopathic) changes, and some no diagnosis. Histochemical studies were done using
156 ATPase and NADH-TR (nicotinamide adenine dinucleotide (NAD) + hydrogen (H) and tetrazolium
157 reductase) stains. Frozen sections of 6 microns were stained with dystrophin 1 (C terminus-mouse
158 monoclonal Dy8\6C5), dystrophin 2 (mid-rod domain mouse monoclonal Dy4\6D3), dysferlin
159 (mouse monoclonal NCL-Hamlet-2), and α (Ad1\20A6), β (Bsarc\5B1), γ (35 DAG\21B5) and δ
160 (Dsarc 3\12C1) sarcoglycan antibodies (Novocastra labs), using peroxidase method and standard
161 controls.

162

163

164 **Molecular Diagnosis by Exome Sequencing**

165 Exome sequencing was performed in a Clinical Laboratory Improvement Amendments and College
166 of American Pathologists (CLIA-CAP)-certified laboratory. Peripheral intravenous blood was
167 collected from enrolled patients into 10-ml commercial tubes containing ethylene-diamine tetraacetic
168 acid (EDTA). These samples were shipped immediately overnight on ice to our laboratory for further
169 analysis. DNA was extracted from whole blood using the Qiagen genomic DNA extraction Kit
170 according to the manufacturer's instructions. We performed exome sequencing using Agilent V5Plus
171 exome capture kit to identify disease causative variants. Sequencing was performed using the
172 Illumina HiSeq 2500 sequencing system with 100-basepair (bp) paired-end reads (similar to
173 bidirectional Sanger sequencing), with an average coverage of 100X in the target region. The target
174 region includes the exon and 10 bp of flanking intronic region. NextGENe software mapped the
175 DNA sequence reads to the published human genome build UCSC hg19 reference sequence. Primary
176 data analysis was also performed using Illumina DRAGEN Bio-IT Platform v.2.03. Secondary and
177 tertiary data analysis was also performed using PerkinElmer's internal ODIN v.1.01 software for
178 SNVs and Biodiscovery's NxClinical v.4.3 or Illumina DRAGEN Bio-IT Platform v.2.03 for copy
179 number variant (CNV) and absence of heterozygosity (AOH). Reads were aligned and filtered as
180 described previously (17, 18). In short, in the filtering process, variants in genes that are not relevant
181 to the patient's clinical phenotypes were filtered in the clinical setting using population-wide minor
182 allele frequency, predicted effect on protein function or splicing, literature evidence, and disease-
183 variant databases such as the Human Gene Mutation Database (<http://www.hgmd.cf.ac.uk>), ClinVar
184 (<http://www.clinvar.com>), Online Mendelian Inheritance of Man
185 (<https://www.ncbi.nlm.nih.gov/omim>), genome Aggregation Database (gnomAD:
186 <https://gnomad.broadinstitute.org/>), and using our internal Emory Genetics Lab (EGL) EmVClass
187 database (<http://www.egl-eurofins.com/emvclass/emvclass.php>). Variants that do not meet QC
188 metrics, such as those with poor coverage (<20 \times), were considered less likely to be real, treated as
189 false positives, and therefore filtered. Variants with a minor allele frequency of >0.01 are
190 polymorphisms by definition and less likely to be pathogenic. Silent changes and intronic variants
191 beyond the consensus splice donor/acceptor sequences or beyond the 10bp intronic flanking
192 sequences are less likely to be pathogenic and were filtered in the analysis unless a known clinically
193 significant rare deep-intronic variant is identified. Rare single nucleotide variants (SNVs) meeting
194 internal quality assessment guidelines are confirmed by Sanger sequence analysis.

195 Molecular diagnosis was performed by classifying variants with clinical data correlation to
196 identify most likely causal disease gene and as per American College of Medical Genetics and
197 Genomics (ACMG) guidelines (19) and with clinical data correlation. Diagnostic yield was
198 calculated based on definitive diagnosis of patients harboring pathogenic or likely pathogenic
199 variants in autosome-recessive/dominant, and X-linked myopathy genes. Prevalence of each
200 identified myopathy subtype identified by our clinical exome sequencing diagnostic program was
201 established and compared. When rare reportable variants in our study were not found in NIH ClinVar

202 (<https://www.ncbi.nlm.nih.gov/clinvar/>), nature of variant, literature evidence and correlation with
203 established specific clinical symptoms of the patient's myopathy was used to identify most likely
204 causal gene and to classify the variant, keeping in mind ACMG guidelines. When no literature
205 evidence was found, the variant was classified based on nature of variant such as nonsense variant or
206 frameshift variant causing a premature stop codon or a stop-loss or a large deletion or duplication in
207 genes known to affect by loss of function modality, as well as correlation with established specific
208 clinical symptoms of the patient's myopathy. High-confidence rare variants were taken as novel
209 when not found in public databases and included in the analysis to interpret relevant disease type
210 causality with clinical correlation. Patient cases with variants of uncertain significances (VUSs) were
211 not included in the molecular diagnostic yield calculations.

212

213

214

215

216

217

218 RESULTS

219

220 Molecular diagnosis of recruited patients

221 A total of 207 unrelated myopathy-suspected patients were recruited in the current study from diverse
222 regions of India with different ethnicities and religion, as well as varied social and marriage customs.
223 Molecular diagnosis was established in 49% (101/207; 95% CI, 42%-56%) of the patients with the
224 majority having pathogenic variants identified in one of the following genes, *GNE* (31%; 31/101),
225 *DYSF* (27%; 27/101), or *CAPN3* (19%; 19/101), indicating that these genes are the major
226 contributors to genetic myopathy in India (Figure 1). Autosomal-recessive forms were much more
227 frequent constituting 95/101 (94%) of the genetically-diagnosed patients. Uncommon autosomal/X-
228 linked recessive-subtypes identified were: 5 sarcoglycanopathies (LGMD R3-R6; 5%), 3
229 anoctaminopathies (LGMD R12 anoctamin-related; 3%), 2 myoadenylate-deaminase-deficiency-
230 myopathies (2%), 2 Pompe disease (2%), 2 telethoninopathies (LGMDR7 telethonin-related; 2%), 1
231 X-linked Emery-Dreifuss-muscular-dystrophy (EDMD1 emerin-related; 1%), 1 Merosin-deficiency-
232 congenital-muscular-dystrophy-type 1 (MDC1 or LGMDR23 laminin α 2-related; 1%), 1 POMT1-
233 proteinopathy (LGMDR11 POMT1-related; 1%). Autosomal-dominant-subtypes were less common
234 with 3 laminopathies (EDMD2; 3%), 1 myotilinopathy (Myofibrillar Myopathy; 1%), and 1 HSP40-
235 proteinopathy (LGMDD1 DNAJB6-related; 1%). 14 patients had no reportable variants and were
236 truly negative for this study.

237 We identified 65 variant alleles comprised of 37 unique variants in the three major genes
238 (*GNE*, *DYSF*, *CAPN3*). A total of 14 unique variants were identified in *GNE* (Figure 2A). The
239 present study confirmed the absence of a mutational hot-spot region in *GNE* in the Indian patients.
240 The majority of the variants detected in *GNE* (12) were missense variants located throughout the
241 *GNE* gene, suggesting an important role of missense changes in causing *GNE*-myopathy in people of
242 Indian subcontinent origin (Table 1). The most common pathogenic variants c.2179G>A (p/V727M)

243 and c.1760T>C/c.1853T>C (p.I587T/p.I618T) were detected in most of the *GNE* patients (Figure
244 2D) with extensive homozygosity observed for the c.1760T>C (p.I587T) common pathogenic
245 variant. Only one nonsense variant c.385C>T (p.R129X), one frameshift variant c.397_398dupAT
246 and no splice site variants were identified in *GNE*.

247 *CAPN3* and *DYSF* are the next major contributing genes in Indian genetic myopathy patients.
248 Calpainopathy (*CAPN3*, LGMDR1) represents the most frequent LGMD-subtype worldwide (6, 20,
249 21), but was the second most common myopathy found in our cohort. No specific mutational hot
250 spot was identified and all 14 identified unique variants in 9 patients were distributed throughout the
251 *CAPN3* gene (Figure 2C). Homozygosity was observed in 4 out of 9 *CAPN3* patients (45%) (Figure
252 2A,B).

253 The 9 unique variants identified in 9 *DYSF* patients were also distributed throughout the
254 *DYSF* gene. Interestingly, we found that 96% (26/27) of the individuals with a dysferlinopathy
255 molecular diagnosis were homozygous for the detected pathogenic variant (Figure 2B), explaining
256 why autosomal recessive disorders like dysferlinopathy are the more common form of inherited
257 myopathy found in India.

258 In addition, the two Pompe genetically diagnosed Indian patients did not have either any
259 homozygous *GAA* variants or the leaky splice-variant c.-32-13T>G, that are more common in adult-
260 onset Pompe in many other populations.

261

262 **Clinical characteristics of genetically-diagnosed patients**

263 Pictorial examples (Figure 3) and details of clinical features of common subtypes (Tables 1-2) and
264 uncommon subtypes (Tables 3-4) of myopathies identified in our Indian cohort are provided. Cardiac
265 involvement was observed in a total of 6 patients: one each for *AMPD1*, *GAA*, *DYSF*, *LMNA*, and
266 two *GNE*-myopathies. Patient# 2 (*AMPD1*) and 38 (*LMNA*: Laminopathy or EDMD) showed
267 atrioventricular conduction blocks, with *AMPD1* patient showing 30% ejection fraction. Patient# 47
268 (*DYSF*) showed proximo-distal weakness and mild sub-clinical cardiomyopathy (ejection fraction
269 50%) resembling few reports of miyoshi myopathy (22, 23). Patient# 73 (*GAA*: Pompe disease) had
270 dilated cardiomyopathy with 32% ejection fraction and also showed respiratory involvement with
271 breathlessness on exertion. Patient # 89 and 90 (*GNE*-myopathies) showed both sub-clinical
272 cardiomyopathy evidenced by mild reduction of ejection fraction on the 2D echocardiography.
273 Among the 6 patients, only the patient # 73 (Pompe disease) showed breathlessness on exertion. Data
274 on pulmonary function tests on any case were not available. Available muscle biopsy results
275 indicated that 66% (31 out of 47) of the patients had dystrophic or myopathic changes with/without
276 inflammation. A total of 4 patients were non-ambulatory and required wheel-chair assistance (Tables
277 1-4 and Table S1 in Supplementary Material).

278 **Common Subtypes**

279 *GNE* myopathy, dysferlinopathy and calpainopathy were identified as the three most common
280 subtypes of inherited myopathies. Normal range of creatine kinase (CK) in this study was 30-160
281 IU/L. The details of the pattern of clinical weakness and uncommon clinical features of these three
282 groups are described below.

283 **GNE-myopathy**

284 The onset-age varied (16-60 years) in 17 females and 14 males. Total duration of illness was between
285 3 months and 30 years with lower limb onset in all except one with upper limb involvement
286 simultaneously. Asymmetry at onset was seen in 13 patients. Creatine kinase (CK) levels ranged
287 between 102-1986 IU/L. Two patients had loss of ambulation with long duration of illness (17 and 13
288 years).

289 *Pattern of weakness:* Most patients had conventional presentation with weakness affecting the
290 tibialis-anterior (TA) maximally along with sparing of the quadriceps. With advancing duration of
291 the disease, patients also showed a degree of weakness in the iliopsoas, adductors of thigh,
292 hamstrings in lower-limbs and biceps and first dorsal interosseous muscles in the upper-limbs
293 (denoted as D+P in Table 2).

294 *Rare clinical features:* Two patients had severe affection of proximal-muscles of the upper-limbs
295 with winging, later into the illness (Table 2).

296

297 **Dysferlinopathy**

298 Onset-age was 13-33 years in 15 males and 12 females. Duration of illness ranged from 1 to 17 years.
299 Weakness began in the lower limbs of all patients: proximo-distal in 7 patients, only proximal in 21
300 patients, and only distal in the remaining 3 patients. Biceps lump was seen in 14 patients. CK levels
301 highly varied and were between 1,018-26,740 IU/L.

302 *Pattern of weakness:* Most patients had proximal-onset of lower-limbs-weakness with maximum
303 affection of iliopsoas, hip adductors, hamstrings, quadriceps, and gastrocnemius muscles. These
304 patients had difficulty in walking on toes, wasting of calves and high CK-levels (Table 2).

305 *Rare clinical features:* Scapular winging and facial weakness was seen in 3 patients, in advanced
306 stages of the disease. Asymmetry of weakness was seen in only 1 patient. This unusual patient had
307 one pathogenic variant in the *ANO5* gene along with a homozygous pathogenic variant in *DYSF*.
308 Interestingly, this patient (patient #50 in Table 5) showed a phenotype common to both
309 dysferlinopathy and anoctaminopathy (high CK, proximal and distal muscle weakness, asymmetrical
310 weakness) and features unusual to both types (facial weakness). Presence of inflammation in muscle
311 biopsy and absence of Dysferlin staining were the manifestations of dysferlinopathy at the
312 histological level.

313

314 **Calpainopathy**

315 Onset-age was 6 to 48 years in 10 males and 9 females. Duration of illness ranged from 1 to 27 years.
316 Lower limb onset of weakness was seen in 21-patients, upper limbs in 2 and upper and lower limbs
317 were simultaneously affected in 1 patient. The weakness was proximal in 18, proximo-distal in 5 and
318 distal in 1 patient. Winging was present in 15/19 and tendo-achilis contractures were seen in 12/19-
319 patients. Loss of ambulation developed in one patient after 27years into the illness. CK levels ranged
320 from 690 to 7000 IU/L.

321 *Pattern of weakness:* Most patients had the conventional proximal weakness-onset in the lower-
322 limbs. Maximum weakness was seen in the hip adductors, iliopsoas, hamstrings, tibialis anterior
323 (TA) and serratus anterior muscles. Tendoachillis contractures and toe-walking was common.

324 *Rare clinical features:* One patient had diamond on quadriceps and biceps lump which is commonly
325 described in dysfelinopathy. One other patient had mild facial weakness.

326

327

328

329 **Clinical features of genetically-diagnosed uncommon subtypes in India**

330 The clinical features of the rare and uncommon genetically diagnosed subtypes found in this study
331 have been provided in Table 4. These individual groups were small consisting of few or a single
332 patient each and were comprised of sarcoglycanopathies (*SGCA/SGCB/SGCD/SGCG*),
333 collagenopathies (*COL6A1/COL6A2/COL6A3*), anoctaminopathy (*ANO5*), telethoninopathy (*TCAP*),
334 Pompe disease (*GAA*), myoadenylate deaminase deficiency myopathy (*AMPD1*), myotilinopathy
335 (*MYOT*), laminopathy (*LMNA*), HSP 40 proteinopathy (*DNAJB6*), Emery Dreifuss muscular
336 dystrophy (*EMD*), POMT1 proteinopathy (*POMT1*), and merosin deficient congenital muscular
337 dystrophy (*LAMA2*). Interestingly, myoadenylate deaminase deficiency myopathy due to *AMPD1*
338 pathogenic variants was only identified in 2 patients out of 207 Indian patient cohort (~1%)
339 suggesting lower prevalence among individuals in the Indian subcontinent area and Asians in
340 general. These 2 patients showed heterogeneous symptoms. One had mild limb girdle weakness with
341 slightly elevated CK-levels (665 IU/L). The second patient was wheelchair bound but with normal
342 CK levels (73 IU/L). Along with having compound heterozygous pathogenic *AMPD1* variants
343 (c.242C>T and c.133C>T), the patient with the severe phenotype also harboured homozygous
344 *CAPN3* pathogenic variant (c.1793_1796delAAAC; patient # 1 or 6), which could be associated with
345 higher clinical severity. These *AMPD1* cases suggest more heterogeneity in the nature of muscle
346 weakness and clinical overlap of *AMPD1*-associated myopathy with limb-girdle features in the
347 Indian population.

348 We also identified 21 patients carrying VUSs in *CAPN3*, *DYSF*, *GNE*, *COL6A1*, *COL6A2*, *COL6A3*,
349 *FLNC*, *SGCB*, *TRIM32* genes that has strong clinical correlation with the gene and corresponding
350 myopathy subtype of interest but without further information reclassify them as likely pathogenic or
351 pathogenic (Table 6). These cases are not included in the diagnosed patients in our cohort. Further
352 segregation and functional studies are needed to confirm these VUSs' pathogenicity.

353

354 **Multigenic myopathies: a novel disease mechanism**

355 Interestingly, 13 patients were identified with pathogenic variants in more than one myopathy
356 genes (Table 5) all showing unusual presentations. We describe below such cases of multigenic
357 unusual presentations identified in this study.

358 Patient# 118 with one pathogenic variant each in the *GNE* (OMIM# 603824) and myotilin
359 (*MYOT*; OMIM#604103) genes. His phenotype largely resembled *GNE*-myopathy with foot-drop
360 and quadriceps-sparing. However, disease-onset was both proximal and distal which also could

361 resemble both subtypes. By the time foot-drop started, difficulty in rising from ground and low chairs
362 had already developed. In this patient, both the genetic abnormalities could be contributing to the
363 proximo-distal presentation resembling both autosomal-dominant myotilinopathy (24) as well as
364 autosomal-recessive GNE-myopathy that has been reported to show early onset of proximal
365 weakness mimicking LGMD especially with hamstring weakness (25). Muscle biopsy staining
366 showed rimmed vacuoles, a common feature of both GNE-myopathy and *MYOT*-related myofibrillar
367 myopathy. Myotilin immunostaining could have helped further but was not available.

368 Patient# 42 had pathogenic variants in the *GNE* gene and additionally harbored one likely
369 pathogenic variant in the dysferlin (*DYSF*) gene. The phenotype was strongly suggestive of a GNE-
370 myopathy, but had onset of proximal muscle weakness and presented a high CK level (1050 IU/L)
371 which are a very well-known presentation of dysferlinopathy suggesting blended phenotype. GNE-
372 myopathy patients are known to have proximal weakness only in later stages of illness. Muscle
373 biopsy confirmed rimmed vacuoles but immunocytochemistry for dysferlin was not available,
374 resembling GNE-myopathy more than dysferlinopathy.

375 Patient# 110 showed the most unusual symptoms: quadriceps-sparing and foot drop
376 resembling GNE-myopathy, but with early and prominent development of scapular-winging and calf-
377 hypertrophy. Interestingly, a heterozygous pathogenic variant in *CAPN3* (OMIM# 114240) and
378 homozygous pathogenic variant in *POMT1* (OMIM# 607423) were present without any *GNE* variant.
379 While the *CAPN3* variant can explain adductor, posterior thigh weakness and scapular winging,
380 *POMT1* variants are known to be associated with hypertrophic calves (26) in limb-girdle muscular
381 dystrophy (LGMDR11). Quadriceps-sparing and prominent foot-drop are unusual in the
382 demonstrated genetic abnormalities.

383 Another patient (patient# 50) with a homozygous pathogenic variant in *DYSF* and a
384 heterozygous pathogenic variant in *ANO5*, showed phenotypes of dysferlinopathy and
385 anoctaminopathy that are representative of both subtypes (calf atrophy, CK of 6390 IU/L, combination
386 of proximal and distal weakness, presence of inflammation in muscle-biopsy, asymmetry of muscle
387 weakness, weakness in dorsiflexors of ankle joints, partial foot drop), and feature unusual to both
388 (facial weakness).

389

390 We identified one patient clinically diagnosed with LGMDR2 but with an unexpected severe
391 progression. This patient had pathogenic variants in both *DYSF* and *MYH2* genes (patient# 47).
392 Heterozygous loss of *MYH2* coupled with complete loss of *DYSF* could be contributing to the rapid
393 disease progression and severe phenotype of both proximal and distal muscle weakness along with
394 cardiac-involvement observed in this individual.

395 Patient# 23 showed homozygous pathogenic variants in both *CAPN3* and *LIMS2* genes suffered
396 from progressive weakness of hip and shoulder girdles. The phenotype consisted of scapular winging,
397 lordosis, severe weakness of hip adductor muscles and mild tendo-achillis contractures, resembling
398 calpainopathies. He also had mild calf hypertrophy. While transient or persistent calf hypertrophy has
399 been documented in calpainopathies(27), it is also a feature of the *LIMS2*-patients. He did not have the
400 triangular tongue or cardiomyopathy seen in *LIMS2*-patients.

401 Patient# 125 had one pathogenic variant each in both *LMNA* and *GNE* genes with limb-girdle
402 pattern of weakness with calf hypertrophy and subclinical cardiac involvement in the form of
403 atrioventricular conduction block. CK level was mildly raised (762 IU/L). All these features are in
404 favor of autosomal-dominant laminopathy. Examination did not reveal any features suggestive of

405 GNE-Myopathy but since *GNE* variants can be segregated either recessively or dominantly,
406 longitudinal patient and family natural history is being followed through.

407 Similar multigenic combinations of pathogenic variants were detected for *GNE*, *ANO5*,
408 *MYOT*, *CAPN3*, *LIMS2*, *COL6A3*, *POMT1*, *CHRNA1*, *EMD*, *PLEC*, *GAA*, *SGCB*, *DMD*, *DOK7*, and
409 *LMNA* genes in a total of 13 individuals (Table 5).

410

411

412

413 **DISCUSSION**

414 Most of the inherited myopathies impose difficulties with physical activity, walking, poor quality of
415 life and ultimately cause a heavy burden on both the affected individuals and their families.
416 Identifying the correct diagnosis of these inherited myopathies can aid in disease management,
417 treatment, and family planning. Clinical diagnosis is based on the distribution of predominant
418 muscle weakness, inheritance mode and associated symptoms but is often highly elusive due to the
419 overlap in clinical presentation. Therefore molecular diagnosis is necessary to confirm the identifying
420 disease-causative gene. This study provides for the first time molecular diagnosis and clinical
421 information on a fairly large cohort-size of genetic myopathies in patients of diverse ethnic
422 backgrounds seen in the Indian subcontinent.

423 This cohort includes a large variety of inherited myopathies including GNE-myopathy,
424 varieties of LGMDs, collagenopathies, metabolic myopathies and related others which have a
425 significant phenotypic-overlap. *GNE*, *DYSF*, and *CAPN3* are the three major genetic contributors to
426 these myopathies, in the Indian subcontinent. Even though we recruited patients from across the
427 Indian subcontinent, as the evaluation was performed in a major single center hospital, there could be
428 limitations to the interpretation of the prevalence. With upcoming or ongoing interventional or
429 natural history study clinical trials on these myopathy subtypes
430 ([https://clinicaltrials.gov/ct2/results?recrs=ab&cond=GNE+Myopathy+&term=&cntry=&state=&city=
431 =&dist=](https://clinicaltrials.gov/ct2/results?recrs=ab&cond=GNE+Myopathy+&term=&cntry=&state=&city=&dist=), <https://www.sarepta.com/science/gene-therapy-engine>), this study will enable cohorts from
432 Indian subcontinent to be included in patient registries that, in turn, will enhance the clinical trials by
433 including different populations with varied ethnicities as well as better monitoring of trial efficacies.
434 Our diagnostic yield of 49% is considerably high with careful clinical correlation of the gene and rare
435 variant identified. Another reason for a high diagnostic yield in an Indian subcontinent cohort is the
436 high prevalence of consanguinity leading to greater homozygosity as found in all the three major
437 contributing genes: *GNE*, *DYSF*, and *CAPN3* (Figure 2B). Moreover, our careful clinical pre-
438 screening with inclusion criteria of genetic myopathies and excluding DMD, FSHD, DM1, DM2,
439 mitochondrial myopathies and acquired myopathies enabled a higher diagnostic yield and further
440 suggests the importance of phenotype correlation of clinical genetic testing results. The clinical
441 features of the three major genetic myopathies followed those mentioned in the literature to a large
442 extent such as GNE myopathy patients with weakness of the tibialis anterior muscles with sparing of
443 quadriceps, dysferlinopathy patients having gastrocnemius weakness and proximal weakness, and
444 calpainopathies having winging of scapulae and hip girdle weakness, mainly of adductor muscles. In
445 addition, GNE-myopathy patients in our cohort also had proximal weakness, possibly representing

446 advanced stages of the disease. The clinical features of the common and uncommon types are
447 summarised in Tables 2 and 4, respectively.

448

449 Molecular findings related to GNE-myopathy patients identified in this study have been
450 reported recently (28) with the most common pathogenic variant in our cohort being the
451 c.1760T>C/c.1853T>C (p.I587T/p.I618T). This variant has recently been described with an ethnic
452 founder effect (29, 30). Moreover, p.V727M is potentially a founder variant in Indian subcontinent
453 since it was seen with high prevalence in our study and previous studies (31-33), and hence this
454 variant is likely present in carriers at higher rates in the Indian subcontinent. This suggests the need
455 for family tracing and carrier testing for inherited rare disorders such as GNE myopathy.

456 Calpainopathy (LGMDR1) was considered a strict autosomal-recessive LGMD-subtype for
457 many years, but patients carrying specific single pathogenic deletion variants in the *CAPN3* gene are
458 reported recently showing dominant disease segregation (6, 34) which was not identified in Indian
459 patients in the current study.

460 Limb-girdle muscular dystrophy type 2B (LGMDR2) and Miyoshi myopathy (MM) caused
461 by variants in the dysferlin gene, *DYSF* (35) are the two major clinical types of dysferlinopathy (36),
462 characterized by proximal muscle-weakness, difficulty in running and climbing stairs, and increased
463 fatigue (37). The higher (96%) homozygosity rate of pathogenic variant in *DYSF* gene explains why
464 autosomal recessive disorders like dysferlinopathy are more common in Indian subcontinent. *DYSF*
465 gene is much larger than some of the other genes such as *GNE* and *CAPN3*, the other two most
466 prevalent myopathy forms in this study. Thus *DYSF* likely harbors more variants and therefore has a
467 higher chance of homozygosity.

468 In this cohort many other more rare genetic myopathies were seen (Tables 3-4, Table S1 in
469 Supplementary Material). Out of these, sarcoglycanopathies and collagenopathies were seen more
470 frequently than other myopathies. The phenotypes of most myopathies were comparable to literature
471 descriptions. There were some unusual clinical features and heterogeneity as well, such as that in
472 *AMPD1* associated myopathy where ranges from mild symptoms to severe limb-girdle features
473 progressing fast to wheel-chair assistance and dilated cardiomyopathy were observed. Only 2
474 *AMPD1*-associated myopathy cases were identified in our Indian subcontinent cohort suggesting
475 lower prevalence in Asia similar to what was shown before in the Japanese population(38), compared
476 to being one of the most common genetic myopathies among Caucasians (1 in 50-100 individuals in
477 general population)(39). The *AMPD1* case with severe clinical symptoms also harboured
478 homozygous pathogenic truncated variant in *CAPN3* which may result in the greater disease severity.
479 Further studies are needed to resolve the gene contributions and for better understanding of
480 *AMPD1*'s clinical significance. The diagnosis of myoadenylate deaminase deficiency is challenging
481 given about 2% of muscle biopsies may have enzyme deficiency without clinical correlation (40-42).
482 Deep phenotyping, immunohistochemical studies, western blot analysis or muscle imaging as well as
483 functional studies are necessary to verify this group of myopathies.

484 The interesting finding of 13 patients with pathogenic variants in more than one myopathy gene
485 (Table 5) and showing unusual presentations suggest a possible role of synergistic-heterozygosity and
486 digenic contribution to unusual myopathies, similar to our recent finding in the US LGMD population
487 (6). Multigenic combinations of pathogenic variants were detected involving 15 genes and 13 patients
488 in this study suggest a high prevalence of synergistic heterozygosity in genetic myopathies. In some

489 cases, the phenotype exhibited features of both the genes (eg: *GNE* and *MYOT*, patient #118; *DYSF*
490 and *ANO5*, patient# 50, in Table 5) and in some patient's phenotype favored one gene over the other
491 (eg: patient# 125, Table 5). In some other case, there were clinical features unexplained by the
492 identified genetic variants such as patient# 110 (Table 5) showing *GNE*-myopathy features without
493 any *GNE* variant but pathogenic variants in *POMT1* and *CAPN3*. Thus, when faced with an atypical
494 phenotype of inherited myopathy, the possibility of pathogenic variants in more than one myopathic
495 gene exists and clinical exome or genome sequencing should be considered. Moreover, result of genetic
496 testing in such multigenic cases need to be interpreted cautiously and muscle immunostaining should
497 be considered. For multigenic myopathies, some cases may be due to genetically unidentified or a
498 novel gene, especially those with heterozygous VUS in genes known to cause only recessive diseases.
499 With widespread use of extensive panels, focused or whole-exome, and genome-sequencing, more
500 such instances will be unearthed, helping further understanding of the pathophysiology and expressions
501 of the genetic abnormalities. Functional omics platforms such as RNA-sequencing, proteomics, and
502 metabolomics (43, 44) of the muscle tissue and segregation studies are needed in these unusual cohorts,
503 to understand the variable expressions of the genes at the effector organ and the phenotypic variability.
504 We propose to carry out this work in future which is a current limitation of this study.

505 True negative findings for the 14 patients with myopathy clinical symptoms suggest the need
506 for whole genome sequencing (WGS) in the future to discover new myopathy causal genes harboring
507 variants such as large deletions or duplication or deep-intronic variants that may have been missed
508 with ES. A study limitation was that even though our inclusion criteria did not have any age
509 restriction for subject recruitment the neuromuscular clinic caters mainly to the adult patients and
510 hence pediatric cases were underrepresented in this study. Though this is a single center study,
511 patients were referred to the center from all over the Indian subcontinent with diverse ethnicities and
512 religious origins. Another limitation of our study was the lack of segregation analysis of compound
513 heterozygous variant combinations identified in patients of our cohort. This is due to difficulty in the
514 current setting in the region based on from where the patients travel and come to clinic and
515 unavailability of parents or children of the patients. Segregation study is needed that will further
516 enhance our understanding of the variant distribution in the population and for better family
517 planning.

518 The paucity of population-based genetic testing in Indian subcontinent in public databases
519 which may lead to insufficiency of minor allele frequency, lack of reports of similar myopathy
520 patient(s) harboring the variant or unavailable functional data is a limitation in this study. Yet, this
521 also points towards the immediate need and importance of studies such as ours on genetic testing
522 with clinical correlation on large Asian cohorts, either disease-specific or general healthy population.

523

524 Finally, to our knowledge, the current study is the first comprehensive clinical-exome
525 sequencing effort on a large genetic myopathy cohort in the Indian subcontinent that has enhanced
526 our understanding of the spectrum of gene-variant-myopathy-subtype landscape in India yielding a
527 high diagnostic rate. In this genomic era, studies such as this in different developing countries and
528 continents on specific disease cohorts with diverse ethnicities will enable enhancement of the
529 repertoire in the global genomic databases such as ExAc (<http://exac.broadinstitute.org/>), gnomAD
530 (<https://gnomad.broadinstitute.org/>) and also country-specific large databases such as the UK100,000
531 Genome project ([https://www.genomicsengland.co.uk/about-genomics-england/the-100000-
532 genomes-project/](https://www.genomicsengland.co.uk/about-genomics-england/the-100000-genomes-project/)), NIH All of US Genomics program (<https://allofus.nih.gov/>) and others for faster
533 and more accurate variant classification, faster enhanced diagnostics, and the understanding of
534 genotype-phenotype correlations.

535

536 **ETHICS STATEMENT**

537 Written, informed consent was obtained from all individuals or minors' parent or legal guardian or
538 next of kin for the publication of any potentially identifiable images or data included in this article.
539 Written informed consents were obtained from all participants of the study for all procedures
540 according to approved Ethics committee Institutional Review Board protocol. All participants
541 (including parents or legal guardians in case of minor patients) were provided pre- and post-test
542 routine genetic counseling.

543 **CONFLICT OF INTEREST**

544 The authors declare that the research was conducted in the absence of any commercial or financial
545 relationships that could be construed as a potential conflict of interest. Dr. Chakravorty reports grants
546 from Muscular Dystrophy Association, and Jain Foundation, during the conduct of the study. Dr.
547 Hegde reports that she is the VP and CSO of Global Lab Services, PerkinElmer, Inc. that does
548 diagnostic testing and has equity in the company without any conflict of interest.

549 **AUTHOR CONTRIBUTIONS**

550 SC and MH had full access to all data in this study and take responsibility for the integrity of the data
551 and the accuracy of the data analysis. SC and MH designed, conceptualized and oversaw the entire
552 study. Acquisition, analysis, or interpretation of data was done by SC, BRRN, SK, MS, AB, RD, PG,
553 LR, and LG. Drafting of the manuscript was done by SC, SK, MS. Critical revision of the manuscript
554 for important intellectual content was done by all authors. Statistical analysis was performed by SC,
555 BRRN, SK, RD, PG, and LR. SC obtained funding. SC, MH and SK supervised the entire study.

556 **ACKNOWLEDGEMENTS**

557 The authors thank the patients and their families for study participation, and the funding sources.

558 **FUNDING**

559 This work is supported by the Jain Foundation Focused Research Grant, Muscular Dystrophy
560 Association Grant (MDA578400), and Sanofi-Genzyme Investigator Sponsored Studies Grant (SGZ-
561 2017-11829) to S.C.

562 B.R.R.N., and M.H. are employees of Perkin Elmer Genomics. M.H. is also an adjunct professor of
563 Georgia Institute of Technology.

564

565

566 **SUPPLEMENTARY MATERIAL**

567 **Supplementary Methods**

568 **Questionnaires for patient recruitment**

569 **Table S1.** Clinical symptoms and gene diagnosis of molecularly diagnosed patients

570

571

572 **DATA AVAILABILITY STATEMENT**

573 The original contributions presented in the study are included in the article/supplementary material;
574 further inquiries can be directed to the corresponding author/s. This data can be found here:
575 <https://doi.org/10.5061/dryad.tmpg4f4w6>

576

577

578

579 **REFERENCES**

- 580 1. Chakravorty S, Berger K, Arafat D, Nallamilli BRR, Subramanian HP, Joseph S, et al.
581 Clinical utility of RNA sequencing to resolve unusual GNE myopathy with a novel promoter
582 deletion. *Muscle Nerve*. 2019;60(1):98-103.
- 583 2. Benarroch L, Bonne G, Rivier F, Hamroun D. The 2020 version of the gene table of
584 neuromuscular disorders (nuclear genome). *Neuromuscular disorders : NMD*. 2019;29(12):980-1018.
- 585 3. Bonne G, Rivier F, Hamroun D. The 2019 version of the gene table of neuromuscular
586 disorders (nuclear genome). *Neuromuscular disorders : NMD*. 2018;28(12):1031-63.
- 587 4. Bonne G, Rivier F, Hamroun D. The 2018 version of the gene table of monogenic
588 neuromuscular disorders (nuclear genome). *Neuromuscular disorders : NMD*. 2017;27(12):1152-83.
- 589 5. Nigro V, Savarese M. Genetic basis of limb-girdle muscular dystrophies: the 2014 update.
590 *Acta Myol*. 2014;33(1):1-12.
- 591 6. Nallamilli BRR, Chakravorty S, Kesari A, Tanner A, Ankala A, Schneider T, et al. Genetic
592 landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients. *Ann Clin*
593 *Transl Neurol*. 2018;5(12):1574-87.
- 594 7. Guglieri M, Magri F, D'Angelo MG, Prella A, Morandi L, Rodolico C, et al. Clinical,
595 molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle
596 muscular dystrophy patients. *Human mutation*. 2008;29(2):258-66.
- 597 8. Rahimov F, Kunkel LM. The cell biology of disease: cellular and molecular mechanisms
598 underlying muscular dystrophy. *J Cell Biol*. 2013;201(4):499-510.
- 599 9. Mahmood OA, Jiang XM. Limb-girdle muscular dystrophies: where next after six decades
600 from the first proposal (Review). *Mol Med Rep*. 2014;9(5):1515-32.
- 601 10. Yu M, Zheng Y, Jin S, Gang Q, Wang Q, Yu P, et al. Mutational spectrum of Chinese LGMD
602 patients by targeted next-generation sequencing. *PLoS One*. 2017;12(4):e0175343.
- 603 11. Savarese M, Di Fruscio G, Torella A, Fiorillo C, Magri F, Fanin M, et al. The genetic basis of
604 undiagnosed muscular dystrophies and myopathies: Results from 504 patients. *Neurology*.
605 2016;87(1):71-6.

- 606 12. Reddy HM, Cho KA, Lek M, Estrella E, Valkanas E, Jones MD, et al. The sensitivity of
607 exome sequencing in identifying pathogenic mutations for LGMD in the United States. *Journal of*
608 *human genetics*. 2017;62(2):243-52.
- 609 13. Majumder PP, Basu A. A genomic view of the peopling and population structure of India.
610 *Cold Spring Harb Perspect Biol*. 2014;7(4):a008540.
- 611 14. Majumder PP. The human genetic history of South Asia. *Curr Biol*. 2010;20(4):R184-7.
- 612 15. Moorjani P, Patterson N, Loh PR, Lipson M, Kiszfali P, Melegh BI, et al. Reconstructing
613 Roma history from genome-wide data. *PLoS One*. 2013;8(3):e58633.
- 614 16. Krithika S, Maji S, Vasulu TS. A microsatellite study to disentangle the ambiguity of
615 linguistic, geographic, ethnic and genetic influences on tribes of India to get a better clarity of the
616 antiquity and peopling of South Asia. *Am J Phys Anthropol*. 2009;139(4):533-46.
- 617 17. Jones MA, Bhide S, Chin E, Ng BG, Rhodenizer D, Zhang VW, et al. Targeted polymerase
618 chain reaction-based enrichment and next generation sequencing for diagnostic testing of congenital
619 disorders of glycosylation. *Genetics in medicine : official journal of the American College of*
620 *Medical Genetics*. 2011;13(11):921-32.
- 621 18. Chakravorty S, Ankala A, Hegde MR. Implementation of Exome Sequencing Assay. In:
622 Netto GJ, Kaul KL, editors. *Genomic Applications in Pathology*. Cham: Springer International
623 Publishing; 2019. p. 261-81.
- 624 19. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines
625 for the interpretation of sequence variants: a joint consensus recommendation of the American
626 College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet*
627 *Med*. 2015;17(5):405-24.
- 628 20. Fanin M, Nascimbeni AC, Fulizio L, Angelini C. The frequency of limb girdle muscular
629 dystrophy 2A in northeastern Italy. *Neuromuscular disorders : NMD*. 2005;15(3):218-24.
- 630 21. Pathak P, Sharma MC, Sarkar C, Jha P, Suri V, Mohd H, et al. Limb girdle muscular
631 dystrophy type 2A in India: a study based on semi-quantitative protein analysis, with clinical and
632 histopathological correlation. *Neurol India*. 2010;58(4):549-54.
- 633 22. Wenzel K, Geier C, Qadri F, Hubner N, Schulz H, Erdmann B, et al. Dysfunction of
634 dysferlin-deficient hearts. *Journal of molecular medicine (Berlin, Germany)*. 2007;85(11):1203-14.
- 635 23. Choi ER, Park SJ, Choe YH, Ryu DR, Chang SA, Choi JO, et al. Early detection of cardiac
636 involvement in Miyoshi myopathy: 2D strain echocardiography and late gadolinium enhancement
637 cardiovascular magnetic resonance. *J Cardiovasc Magn Reson*. 2010;12:31.
- 638 24. Olivé M, Goldfarb LG, Shatunov A, Fischer D, Ferrer I. Myotilinopathy: refining the clinical
639 and myopathological phenotype. *Brain : a journal of neurology*. 2005;128(Pt 10):2315-26.
- 640 25. Park YE, Kim HS, Choi ES, Shin JH, Kim SY, Son EH, et al. Limb-girdle phenotype is
641 frequent in patients with myopathy associated with GNE mutations. *Journal of the neurological*
642 *sciences*. 2012;321(1-2):77-81.
- 643 26. Balci B, Uyanik G, Dincer P, Gross C, Willer T, Talim B, et al. An autosomal recessive limb
644 girdle muscular dystrophy (LGMD2) with mild mental retardation is allelic to Walker-Warburg
645 syndrome (WWS) caused by a mutation in the POMT1 gene. *Neuromuscul Disord*. 2005;15(4):271-
646 5.

- 647 27. Fardeau M, Hillaire D, Mignard C, Feingold N, Feingold J, Mignard D, et al. Juvenile limb-
648 girdle muscular dystrophy: Clinical, histopathological and genetic data from a small community
649 living in the Reunion Island. *Brain : a journal of neurology*. 1996;119(1):295-308.
- 650 28. Khadilkar SV, Nallamilli BRR, Bhutada A, Hegde M, Gandhi K, Faldu HD, et al. A report on
651 GNE myopathy: Individuals of Rajasthan ancestry share the Roma gene. *Journal of the neurological
652 sciences*. 2017;375:239-40.
- 653 29. Celeste FV, Vilboux T, Ciccone C, de Dios JK, Malicdan MC, Leoyklang P, et al. Mutation
654 update for GNE gene variants associated with GNE myopathy. *Hum Mutat*. 2014;35(8):915-26.
- 655 30. Chamova T, Guerguelcheva V, Gospodinova M, Krause S, Cirak S, Kaprelyan A, et al. GNE
656 myopathy in Roma patients homozygous for the p.I618T founder mutation. *Neuromuscul Disord*.
657 2015;25(9):713-8.
- 658 31. Nalini A, Gayathri N, Nishino I, Hayashi YK. GNE myopathy in India. *Neurol India*.
659 2013;61(4):371-4.
- 660 32. Nishino I, Carrillo-Carrasco N, Argov Z. GNE myopathy: current update and future therapy. *J
661 Neurol Neurosurg Psychiatry*. 2015;86(4):385-92.
- 662 33. Argov Z, Mitrani Rosenbaum S. GNE Myopathy: Two Clusters with History and Several
663 Founder Mutations. *J Neuromuscul Dis*. 2015;2(s2):S73-S6.
- 664 34. Vissing J, Barresi R, Witting N, Van Ghelue M, Gammelgaard L, Bindoff LA, et al. A
665 heterozygous 21-bp deletion in CAPN3 causes dominantly inherited limb girdle muscular dystrophy.
666 *Brain*. 2016;139(Pt 8):2154-63.
- 667 35. Liu J, Aoki M, Illa I, Wu C, Fardeau M, Angelini C, et al. Dysferlin, a novel skeletal muscle
668 gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. *Nat Genet*.
669 1998;20(1):31-6.
- 670 36. Urtizbera JA, Bassez G, Leturcq F, Nguyen K, Krahn M, Levy N. Dysferlinopathies. *Neurol
671 India*. 2008;56(3):289-97.
- 672 37. Prella A, Sciacco M, Tancredi L, Fagiolari G, Comi GP, Ciscato P, et al. Clinical,
673 morphological and immunological evaluation of six patients with dysferlin deficiency. *Acta
674 Neuropathol*. 2003;105(6):537-42.
- 675 38. Morisaki H, Higuchi I, Abe M, Osame M, Morisaki T. First missense mutations (R388W and
676 R425H) of AMPD1 accompanied with myopathy found in a Japanese patient. *Hum Mutat*.
677 2000;16(6):467-72.
- 678 39. Gross M, Rotzer E, Kolle P, Mortier W, Reichmann H, Goebel HH, et al. A G468-T AMPD1
679 mutant allele contributes to the high incidence of myoadenylate deaminase deficiency in the
680 Caucasian population. *Neuromuscul Disord*. 2002;12(6):558-65.
- 681 40. Norman B, Glenmark B, Jansson E. Muscle AMP deaminase deficiency in 2% of a healthy
682 population. *Muscle Nerve*. 1995;18(2):239-41.
- 683 41. Verzijl HT, van Engelen BG, Luyten JA, Steenbergen GC, van den Heuvel LP, ter Laak HJ,
684 et al. Genetic characteristics of myoadenylate deaminase deficiency. *Annals of neurology*.
685 1998;44(1):140-3.
- 686 42. Norman B, Mahnke-Zizelman DK, Vallis A, Sabina RL. Genetic and other determinants of
687 AMP deaminase activity in healthy adult skeletal muscle. *Journal of applied physiology (Bethesda,
688 Md : 1985)*. 1998;85(4):1273-8.

- 689 43. Chakravorty S, Hegde M. Inferring the effect of genomic variation in the new era of
690 genomics. *Hum Mutat.* 2018;39(6):756-73.
- 691 44. Vladutiu GD. Heterozygosity: an expanding role in proteomics. *Mol Genet Metab.*
692 2001;74(1-2):51-63.
- 693 45. de Morrée A, Lutje Hulsik D, Impagliazzo A, van Haagen HHHBM, de Galan P, van
694 Remoortere A, et al. Calpain 3 Is a Rapid-Action, Unidirectional Proteolytic Switch Central to
695 Muscle Remodeling. *PLOS ONE.* 2010;5(8):e11940.
- 696 46. Fanin M, Fulizio L, Nascimbeni AC, Spinazzi M, Piluso G, Ventriglia VM, et al. Molecular
697 diagnosis in LGMD2A: mutation analysis or protein testing? *Hum Mutat.* 2004;24(1):52-62.
- 698 47. Groen EJ, Charlton R, Barresi R, Anderson LV, Eagle M, Hudson J, et al. Analysis of the UK
699 diagnostic strategy for limb girdle muscular dystrophy 2A. *Brain : a journal of neurology.*
700 2007;130(Pt 12):3237-49.
- 701 48. Shirafuji T, Otsuka Y, Kobessho H, Minami N, Hayashi Y, Nishino I, et al. [Case of
702 LGMD2A (calpainopathy) clinically presenting as Miyoshi distal myopathy]. *Rinsho shinkeigaku =*
703 *Clinical neurology.* 2008;48(9):651-5.
- 704 49. Sáenz A, Leturcq F, Cobo AM, Poza JJ, Ferrer X, Otaegui D, et al. LGMD2A: genotype-
705 phenotype correlations based on a large mutational survey on the calpain 3 gene. *Brain : a journal of*
706 *neurology.* 2005;128(Pt 4):732-42.
- 707 50. Richard I, Roudaut C, Saenz A, Pogue R, Grimbergen JE, Anderson LV, et al.
708 Calpainopathy-a survey of mutations and polymorphisms. *Am J Hum Genet.* 1999;64(6):1524-40.
- 709 51. Khadilkar SV, Chaudhari CR, Dastur RS, Gaitonde PS, Yadav JG. Limb-girdle muscular
710 dystrophy in the Agarwals: Utility of founder mutations in CAPN3 gene. *Annals of Indian Academy*
711 *of Neurology.* 2016;19(1):108-11.
- 712 52. Ankala A, Kohn JN, Dastur R, Gaitonde P, Khadilkar SV, Hegde MR. Ancestral founder
713 mutations in calpain-3 in the Indian Agarwal community: historical, clinical, and molecular
714 perspective. *Muscle Nerve.* 2013;47(6):931-7.
- 715 53. Todorova A, Kress W, Mueller C. Novel mutations in the calpain 3 gene in Germany.
716 *Clinical genetics.* 2005;67(4):356-8.
- 717 54. Nilsson MI, Macneil LG, Kitaoka Y, Alqarni F, Suri R, Akhtar M, et al. Redox state and
718 mitochondrial respiratory chain function in skeletal muscle of LGMD2A patients. *PLoS One.*
719 2014;9(7):e102549.
- 720 55. Piluso G, Politano L, Aurino S, Fanin M, Ricci E, Ventriglia VM, et al. Extensive scanning of
721 the calpain-3 gene broadens the spectrum of LGMD2A phenotypes. *J Med Genet.* 2005;42(9):686-
722 93.
- 723 56. Krahn M, Lopez de Munain A, Streichenberger N, Bernard R, Pécheux C, Testard H, et al.
724 CAPN3 mutations in patients with idiopathic eosinophilic myositis. *Annals of neurology.*
725 2006;59(6):905-11.
- 726 57. Krahn M, Pécheux C, Chapon F, Bérout C, Drouin-Garraud V, Laforet P, et al.
727 Transcriptional explorations of CAPN3 identify novel splicing mutations, a large-sized genomic
728 deletion and evidence for messenger RNA decay. *Clinical genetics.* 2007;72(6):582-92.

- 729 58. Blázquez L, Azpitarte M, Sáenz A, Goicoechea M, Otaegui D, Ferrer X, et al.
730 Characterization of novel CAPN3 isoforms in white blood cells: an alternative approach for limb-
731 girdle muscular dystrophy 2A diagnosis. *Neurogenetics*. 2008;9(3):173-82.
- 732 59. Bartoli M, Desvignes JP, Nicolas L, Martin K. Exome sequencing as a second-tier diagnostic
733 approach for clinically suspected dysferlinopathy patients. *Muscle Nerve*. 2014;50(6):1007-10.
- 734 60. Krahn M, Goicoechea M, Hanisch F, Groen E, Bartoli M, Pécheux C, et al. Eosinophilic
735 infiltration related to CAPN3 mutations: a pathophysiological component of primary calpainopathy?
736 *Clinical genetics*. 2011;80(4):398-402.
- 737 61. Balci B, Aurino S, Haliloglu G, Talim B, Erdem S, Akcören Z, et al. Calpain-3 mutations in
738 Turkey. *European journal of pediatrics*. 2006;165(5):293-8.
- 739 62. Stehlikova K, Skalova D, Zidkova J, Mrazova L, Vondracek P, Mazanec R, et al. Autosomal
740 recessive limb-girdle muscular dystrophies in the Czech Republic. *BMC Neurol*. 2014;14:154.
- 741 63. Krahn M, Bernard R, Pecheux C, Hammouda el H, Eymard B, Lopez de Munain A, et al.
742 Screening of the CAPN3 gene in patients with possible LGMD2A. *Clinical genetics*. 2006;69(5):444-
743 9.
- 744 64. Xi J, Blandin G, Lu J, Luo S, Zhu W, Bérout C, et al. Clinical heterogeneity and a high
745 proportion of novel mutations in a Chinese cohort of patients with dysferlinopathy. *Neurol India*.
746 2014;62(6):635-9.
- 747 65. Krahn M, Bérout C, Labelle V, Nguyen K, Bernard R, Bassez G, et al. Analysis of the DYSF
748 mutational spectrum in a large cohort of patients. *Hum Mutat*. 2009;30(2):E345-75.
- 749 66. Aoki M, Liu J, Richard I, Bashir R, Britton S, Keers SM, et al. Genomic organization of the
750 dysferlin gene and novel mutations in Miyoshi myopathy. *Neurology*. 2001;57(2):271-8.
- 751 67. Jin SQ, Yu M, Zhang W, Lyu H, Yuan Y, Wang ZX. Dysferlin Gene Mutation Spectrum in a
752 Large Cohort of Chinese Patients with Dysferlinopathy. *Chinese medical journal*.
753 2016;129(19):2287-93.
- 754 68. Huang Y, Verheesen P, Roussis A, Frankhuizen W, Ginjaar I, Haldane F, et al. Protein
755 studies in dysferlinopathy patients using llama-derived antibody fragments selected by phage display.
756 *European journal of human genetics : EJHG*. 2005;13(6):721-30.
- 757 69. Rosales XQ, Gastier-Foster JM, Lewis S, Vinod M, Thrush DL, Astbury C, et al. Novel
758 diagnostic features of dysferlinopathies. *Muscle Nerve*. 2010;42(1):14-21.
- 759 70. Nguyen K, Bassez G, Krahn M, Bernard R, Laforêt P, Labelle V, et al. Phenotypic study in
760 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. *Arch Neurol*.
761 2007;64(8):1176-82.
- 762 71. Vincent AE, Rosa HS, Alston CL, Grady JP, Rygiel KA, Rocha MC, et al. Dysferlin
763 mutations and mitochondrial dysfunction. *Neuromuscul Disord*. 2016;26(11):782-8.
- 764 72. Middel V, Zhou L, Takamiya M, Beil T, Shahid M, Roostalu U, et al. Dysferlin-mediated
765 phosphatidylserine sorting engages macrophages in sarcolemma repair. *Nature communications*.
766 2016;7:12875.
- 767 73. Szymanska S, Rokicki D, Karkucinska-Wieckowska A, Szymanska-Debinska T, Ciara E,
768 Ploski R, et al. Case report of an adolescent girl with limb-girdle muscular dystrophy type 2B - the
769 usefulness of muscle protein immunostaining in the diagnosis of dysferlinopathies. *Folia*
770 *neuropathologica*. 2014;52(4):452-6.

- 771 74. Gallardo E, de Luna N, Diaz-Manera J, Rojas-García R, Gonzalez-Quereda L, Flix B, et al.
772 Comparison of dysferlin expression in human skeletal muscle with that in monocytes for the
773 diagnosis of dysferlin myopathy. *PLoS One*. 2011;6(12):e29061.
- 774 75. Turan S, Farruggio AP, Srifa W, Day JW, Calos MP. Precise Correction of Disease Mutations
775 in Induced Pluripotent Stem Cells Derived From Patients With Limb Girdle Muscular Dystrophy.
776 *Molecular therapy : the journal of the American Society of Gene Therapy*. 2016;24(4):685-96.
- 777 76. Stehlíková K, Skálová D, Zídková J, Haberlová J, Vohánka S, Mazanec R, et al. Muscular
778 dystrophies and myopathies: the spectrum of mutated genes in the Czech Republic. *Clinical genetics*.
779 2017;91(3):463-9.
- 780 77. Klinge L, Aboumoussa A, Eagle M, Hudson J, Sarkozy A, Vita G, et al. New aspects on
781 patients affected by dysferlin deficient muscular dystrophy. *J Neurol Neurosurg Psychiatry*.
782 2010;81(9):946-53.
- 783 78. Vilchez JJ, Gallano P, Gallardo E, Lasa A, Rojas-García R, Freixas A, et al. Identification of
784 a novel founder mutation in the DYSF gene causing clinical variability in the Spanish population.
785 *Arch Neurol*. 2005;62(8):1256-9.
- 786 79. Bean LJ, Tinker SW, da Silva C, Hegde MR. Free the data: one laboratory's approach to
787 knowledge-based genomic variant classification and preparation for EMR integration of genomic
788 data. *Hum Mutat*. 2013;34(9):1183-8.
- 789 80. Park YE, Kim HS, Lee CH, Nam TS, Choi YC, Kim DS. Two common mutations
790 (p.Gln832X and c.663+1G>C) account for about a third of the DYSF mutations in Korean patients
791 with dysferlinopathy. *Neuromuscul Disord*. 2012;22(6):505-10.
- 792 81. Lo HP, Cooper ST, Evesson FJ, Seto JT, Chiotis M, Tay V, et al. Limb-girdle muscular
793 dystrophy: diagnostic evaluation, frequency and clues to pathogenesis. *Neuromuscul Disord*.
794 2008;18(1):34-44.
- 795 82. Harris E, Bladen CL, Mayhew A, James M, Bettinson K, Moore U, et al. The Clinical
796 Outcome Study for dysferlinopathy: An international multicenter study. *Neurol Genet*.
797 2016;2(4):e89.
- 798 83. Dastur RS, Gaitonde PS, Kachwala M, Nallamilli BRR, Ankala A, Khadilkar SV, et al.
799 Detection of Dysferlin Gene Pathogenic Variants in the Indian Population in Patients Predicted to
800 have a Dysferlinopathy Using a Blood-based Monocyte Assay and Clinical Algorithm: A Model for
801 Accurate and Cost-effective Diagnosis. *Annals of Indian Academy of Neurology*. 2017;20(3):302-8.
- 802 84. Dominov JA, Uyan O, McKenna-Yasek D, Nallamilli BRR, Kergourlay V, Bartoli M, et al.
803 Correction of pseudoexon splicing caused by a novel intronic dysferlin mutation. *Ann Clin Transl*
804 *Neurol*. 2019;6(4):642-54.
- 805 85. Winckler PB, da Silva AMS, Coimbra-Neto AR, Carvalho E, Cavalcanti EBU, Sobreira CFR,
806 et al. Clinicogenetic lessons from 370 patients with autosomal recessive limb-girdle muscular
807 dystrophy. *Clinical genetics*. 2019;96(4):341-53.
- 808 86. Carrillo N, Malicdan MC, Huizing M. GNE Myopathy. In: Adam MP, Ardinger HH, Pagon
809 RA, Wallace SE, Bean LJH, Stephens K, et al., editors. *GeneReviews*(®). Seattle (WA): University
810 of Washington, Seattle
- 811 Copyright © 1993-2020, University of Washington, Seattle. GeneReviews is a registered trademark
812 of the University of Washington, Seattle. All rights reserved.; 1993.

- 813 87. Eisenberg I, Avidan N, Potikha T, Hochner H, Chen M, Olender T, et al. The UDP-N-
814 acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary
815 inclusion body myopathy. *Nature genetics*. 2001;29(1):83-7.
- 816 88. Argov Z, Eisenberg I, Grabov-Nardini G, Sadeh M, Wirguin I, Soffer D, et al. Hereditary
817 inclusion body myopathy: the Middle Eastern genetic cluster. *Neurology*. 2003;60(9):1519-23.
- 818 89. Cho A, Hayashi YK, Monma K, Oya Y, Noguchi S, Nonaka I, et al. Mutation profile of the
819 GNE gene in Japanese patients with distal myopathy with rimmed vacuoles (GNE myopathy). *J*
820 *Neurol Neurosurg Psychiatry*. 2014;85(8):914-7.
- 821 90. Chaouch A, Brennan KM, Hudson J, Longman C, McConville J, Morrison PJ, et al. Two
822 recurrent mutations are associated with GNE myopathy in the North of Britain. *J Neurol Neurosurg*
823 *Psychiatry*. 2014;85(12):1359-65.
- 824 91. Cerino M, Gorokhova S, Béhin A, Urtizberea JA, Kergourlay V, Salvo E, et al. Novel
825 Pathogenic Variants in a French Cohort Widen the Mutational Spectrum of GNE Myopathy. *J*
826 *Neuromuscul Dis*. 2015;2(2):131-6.
- 827 92. Saechao C, Valles-Ayoub Y, Esfandiari S, Haghghatgoo A, No D, Shook S, et al. Novel
828 GNE mutations in hereditary inclusion body myopathy patients of non-Middle Eastern descent.
829 *Genetic testing and molecular biomarkers*. 2010;14(2):157-62.
- 830 93. de Dios JK, Shrader JA, Joe GO, McClean JC, Williams K, Evers R, et al. Atypical
831 presentation of GNE myopathy with asymmetric hand weakness. *Neuromuscul Disord*.
832 2014;24(12):1063-7.
- 833 94. Park YE, Kim DS, Choi YC, Shin JH. Progression of GNE Myopathy Based on the Patient-
834 Reported Outcome. *Journal of clinical neurology (Seoul, Korea)*. 2019;15(3):275-84.
- 835 95. Chen Y, Xi J, Zhu W, Lin J, Luo S, Yue D, et al. GNE myopathy in Chinese population:
836 hotspot and novel mutations. *Journal of human genetics*. 2019;64(1):11-6.
- 837 96. Zhao J, Wang Z, Hong D, Lv H, Zhang W, Chen J, et al. Mutational spectrum and clinical
838 features in 35 unrelated mainland Chinese patients with GNE myopathy. *Journal of the neurological*
839 *sciences*. 2015;354(1-2):21-6.
- 840 97. No D, Valles-Ayoub Y, Carbajo R, Khokher Z, Sandoval L, Stein B, et al. Novel GNE
841 mutations in autosomal recessive hereditary inclusion body myopathy patients. *Genetic testing and*
842 *molecular biomarkers*. 2013;17(5):376-82.
- 843 98. Morisaki T, Gross M, Morisaki H, Pongratz D, Zöllner N, Holmes EW. Molecular basis of
844 AMP deaminase deficiency in skeletal muscle. *Proceedings of the National Academy of Sciences of*
845 *the United States of America*. 1992;89(14):6457-61.
- 846 99. Castro-Gago M, Gómez-Lado C, Pérez-Gay L, Eirís-Puñal J, Martínez EP, García-Consuegra
847 I, et al. Primary adenosine monophosphate (AMP) deaminase deficiency in a hypotonic infant. *J*
848 *Child Neurol*. 2011;26(6):734-7.
- 849 100. Johnston JJ, Lewis KL, Ng D, Singh LN, Wynter J, Brewer C, et al. Individualized iterative
850 phenotyping for genome-wide analysis of loss-of-function mutations. *Am J Hum Genet*.
851 2015;96(6):913-25.
- 852 101. Luciola S, Giusti B, Mercuri E, Vanegas OC, Lucarini L, Pietroni V, et al. Detection of
853 common and private mutations in the COL6A1 gene of patients with Bethlem myopathy. *Neurology*.
854 2005;64(11):1931-7.

- 855 102. Trempe JF, Sauvé V, Grenier K, Seirafi M, Tang MY, Ménade M, et al. Structure of parkin
856 reveals mechanisms for ubiquitin ligase activation. *Science (New York, NY)*. 2013;340(6139):1451-
857 5.
- 858 103. Lamandé SR, Shields KA, Kornberg AJ, Shield LK, Bateman JF. Bethlem myopathy and
859 engineered collagen VI triple helical deletions prevent intracellular multimer assembly and protein
860 secretion. *The Journal of biological chemistry*. 1999;274(31):21817-22.
- 861 104. Pan TC, Zhang RZ, Sudano DG, Marie SK, Bönnemann CG, Chu ML. New molecular
862 mechanism for Ullrich congenital muscular dystrophy: a heterozygous in-frame deletion in the
863 COL6A1 gene causes a severe phenotype. *Am J Hum Genet*. 2003;73(2):355-69.
- 864 105. Baker NL, Mörgelin M, Pace RA, Peat RA, Adams NE, Gardner RJ, et al. Molecular
865 consequences of dominant Bethlem myopathy collagen VI mutations. *Annals of neurology*.
866 2007;62(4):390-405.
- 867 106. Fan Y, Liu A, Wei C, Yang H, Chang X, Wang S, et al. Genetic and clinical findings in a
868 Chinese cohort of patients with collagen VI-related myopathies. *Clinical genetics*. 2018;93(6):1159-
869 71.
- 870 107. Lampe AK, Dunn DM, von Niederhausern AC, Hamil C, Aoyagi A, Laval SH, et al.
871 Automated genomic sequence analysis of the three collagen VI genes: applications to Ullrich
872 congenital muscular dystrophy and Bethlem myopathy. *J Med Genet*. 2005;42(2):108-20.
- 873 108. Butterfield RJ, Foley AR, Dastgir J, Asman S, Dunn DM, Zou Y, et al. Position of glycine
874 substitutions in the triple helix of COL6A1, COL6A2, and COL6A3 is correlated with severity and
875 mode of inheritance in collagen VI myopathies. *Hum Mutat*. 2013;34(11):1558-67.
- 876 109. Long CG, Braswell E, Zhu D, Apigo J, Baum J, Brodsky B. Characterization of collagen-like
877 peptides containing interruptions in the repeating Gly-X-Y sequence. *Biochemistry*.
878 1993;32(43):11688-95.
- 879 110. Parini R, De Lorenzo P, Dardis A, Burlina A, Cassio A, Cavarzere P, et al. Long term clinical
880 history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement
881 therapy. *Orphanet J Rare Dis*. 2018;13(1):32.
- 882 111. Fukuhara Y, Fuji N, Yamazaki N, Hirakiyama A, Kamioka T, Seo JH, et al. A molecular
883 analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan.
884 *Molecular genetics and metabolism reports*. 2018;14:3-9.
- 885 112. Pittis MG, Donnarumma M, Montalvo AL, Dominissini S, Kroos M, Rosano C, et al.
886 Molecular and functional characterization of eight novel GAA mutations in Italian infants with
887 Pompe disease. *Hum Mutat*. 2008;29(6):E27-36.
- 888 113. Remiche G, Ronchi D, Magri F, Lamperti C, Bordoni A, Moggio M, et al. Extended
889 phenotype description and new molecular findings in late onset glycogen storage disease type II: a
890 northern Italy population study and review of the literature. *Journal of neurology*. 2014;261(1):83-97.
- 891 114. Bali DS, Goldstein JL, Banugaria S, Dai J, Mackey J, Rehder C, et al. Predicting cross-
892 reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons
893 learned from 10 years of clinical laboratory testing experience. *American journal of medical genetics*
894 *Part C, Seminars in medical genetics*. 2012;160c(1):40-9.
- 895 115. Hermans MM, van Leenen D, Kroos MA, Beesley CE, Van Der Ploeg AT, Sakuraba H, et al.
896 Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the
897 genotype-phenotype correlation in glycogen storage disease type II. *Hum Mutat*. 2004;23(1):47-56.

- 898 116. Löscher WN, Huemer M, Stulnig TM, Simschitz P, Iglseider S, Eggers C, et al. Pompe disease
899 in Austria: clinical, genetic and epidemiological aspects. *Journal of neurology*. 2018;265(1):159-64.
- 900 117. Turaça LT, de Faria DO, Kyosen SO, Teixeira VD, Motta FL, Pessoa JG, et al. Novel GAA
901 mutations in patients with Pompe disease. *Gene*. 2015;561(1):124-31.
- 902 118. Fu L, Qiu W, Yu Y, Guo Y, Zhao P, Zhang X, et al. Clinical and molecular genetic study of
903 infantile-onset Pompe disease in Chinese patients: identification of 6 novel mutations. *Gene*.
904 2014;535(1):53-9.
- 905 119. Beltran Papsdorf TB, Howard JF, Jr., Chahin N. Pearls & Oysters: clues to the diagnosis of
906 adult-onset acid maltase deficiency. *Neurology*. 2014;82(9):e73-5.
- 907 120. Bali DS, Tolun AA, Goldstein JL, Dai J, Kishnani PS. Molecular analysis and protein
908 processing in late-onset Pompe disease patients with low levels of acid α -glucosidase activity.
909 *Muscle Nerve*. 2011;43(5):665-70.
- 910 121. Liao HC, Chiang CC, Niu DM, Wang CH, Kao SM, Tsai FJ, et al. Detecting multiple
911 lysosomal storage diseases by tandem mass spectrometry--a national newborn screening program in
912 Taiwan. *Clinica chimica acta; international journal of clinical chemistry*. 2014;431:80-6.
- 913 122. Oliveira J, Santos R, Soares-Silva I, Jorge P, Vieira E, Oliveira ME, et al. LAMA2 gene
914 analysis in a cohort of 26 congenital muscular dystrophy patients. *Clinical genetics*. 2008;74(6):502-
915 12.
- 916 123. Rajakulendran S, Parton M, Holton JL, Hanna MG. Clinical and pathological heterogeneity in
917 late-onset partial merosin deficiency. *Muscle Nerve*. 2011;44(4):590-3.
- 918 124. Beytía Mde L, Dekomien G, Hoffjan S, Haug V, Anastasopoulos C, Kirschner J. High
919 creatine kinase levels and white matter changes: clinical and genetic spectrum of congenital muscular
920 dystrophies with laminin alpha-2 deficiency. *Molecular and cellular probes*. 2014;28(4):118-22.
- 921 125. Pugh TJ, Kelly MA, Gowrisankar S, Hynes E, Seidman MA, Baxter SM, et al. The landscape
922 of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing. *Genet Med*.
923 2014;16(8):601-8.
- 924 126. Walsh R, Thomson KL, Ware JS, Funke BH, Woodley J, McGuire KJ, et al. Reassessment of
925 Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples.
926 *Genet Med*. 2017;19(2):192-203.
- 927 127. Forissier JE, Bonne G, Bouchier C, Duboscq-Bidot L, Richard P, Briault S, et al. [Apical left
928 ventricular aneurysm without atrio-ventricular block due to a lamin A/C gene mutation]. *Archives
929 des maladies du coeur et des vaisseaux*. 2005;98(1):67-70.
- 930 128. Hookana E, Junttila MJ, Särkioja T, Sormunen R, Niemelä M, Raatikainen MJ, et al. Cardiac
931 arrest and left ventricular fibrosis in a Finnish family with the lamin A/C mutation. *Journal of
932 cardiovascular electrophysiology*. 2008;19(7):743-7.
- 933 129. Forissier JF, Bonne G, Bouchier C, Duboscq-Bidot L, Richard P, Wisniewski C, et al. Apical
934 left ventricular aneurysm without atrio-ventricular block due to a lamin A/C gene mutation. *European
935 journal of heart failure*. 2003;5(6):821-5.
- 936 130. Lakdawala NK, Funke BH, Baxter S, Cirino AL, Roberts AE, Judge DP, et al. Genetic testing
937 for dilated cardiomyopathy in clinical practice. *Journal of cardiac failure*. 2012;18(4):296-303.

- 938 131. Dialynas G, Flannery KM, Zirbel LN, Nagy PL, Mathews KD, Moore SA, et al. LMNA
939 variants cause cytoplasmic distribution of nuclear pore proteins in *Drosophila* and human muscle.
940 *Hum Mol Genet.* 2012;21(7):1544-56.
- 941 132. Dittmer TA, Sahni N, Kubben N, Hill DE, Vidal M, Burgess RC, et al. Systematic
942 identification of pathological lamin A interactors. *Molecular biology of the cell.* 2014;25(9):1493-
943 510.
- 944 133. Benedetti S, Menditto I, Degano M, Rodolico C, Merlini L, D'Amico A, et al. Phenotypic
945 clustering of lamin A/C mutations in neuromuscular patients. *Neurology.* 2007;69(12):1285-92.
- 946 134. Pasqualin LM, Reed UC, Costa TV, Quedas E, Albuquerque MA, Resende MB, et al.
947 Congenital muscular dystrophy with dropped head linked to the LMNA gene in a Brazilian cohort.
948 *Pediatric neurology.* 2014;50(4):400-6.
- 949 135. Fokkema IF, Taschner PE, Schaafsma GC, Celli J, Laros JF, den Dunnen JT. LOVD v.2.0:
950 the next generation in gene variant databases. *Hum Mutat.* 2011;32(5):557-63.
- 951 136. Quijano-Roy S, Mbieleu B, Bönnemann CG, Jeannot PY, Colomer J, Clarke NF, et al. De
952 novo LMNA mutations cause a new form of congenital muscular dystrophy. *Annals of neurology.*
953 2008;64(2):177-86.
- 954 137. Godfrey C, Clement E, Mein R, Brockington M, Smith J, Talim B, et al. Refining genotype–
955 phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. *Brain :
956 a journal of neurology.* 2007;130(10):2725-35.
- 957 138. Carrié A, Piccolo F, Leturcq F, de Toma C, Azibi K, Beldjord C, et al. Mutational diversity
958 and hot spots in the alpha-sarcoglycan gene in autosomal recessive muscular dystrophy (LGMD2D).
959 *J Med Genet.* 1997;34(6):470-5.
- 960 139. van der Kooi AJ, Frankhuizen WS, Barth PG, Howeler CJ, Padberg GW, Spaans F, et al.
961 Limb-girdle muscular dystrophy in the Netherlands: gene defect identified in half the families.
962 *Neurology.* 2007;68(24):2125-8.
- 963 140. Duggan DJ, Gorospe JR, Fanin M, Hoffman EP, Angelini C. Mutations in the sarcoglycan
964 genes in patients with myopathy. *The New England journal of medicine.* 1997;336(9):618-24.
- 965 141. Khadilkar SV, Singh RK, Hegde M, Urtizbera A, Love DR, Chong B. Spectrum of
966 mutations in sarcoglycan genes in the Mumbai region of western India: high prevalence of 525del T.
967 *Neurol India.* 2009;57(4):406-10.
- 968 142. Duggan DJ, Manchester D, Stears KP, Mathews DJ, Hart C, Hoffman EP. Mutations in the
969 delta-sarcoglycan gene are a rare cause of autosomal recessive limb-girdle muscular dystrophy
970 (LGMD2). *Neurogenetics.* 1997;1(1):49-58.
- 971 143. Barresi R, Morris C, Hudson J, Curtis E, Pickthall C, Bushby K, et al. Conserved expression
972 of truncated telethonin in a patient with limb-girdle muscular dystrophy 2G. *Neuromuscul Disord.*
973 2015;25(4):349-52.
- 974 144. Ruggieri A, Brancati F, Zanotti S, Maggi L, Pasanisi MB, Saredi S, et al. Complete loss of the
975 DNAJB6 G/F domain and novel missense mutations cause distal-onset DNAJB6 myopathy. *Acta
976 neuropathologica communications.* 2015;3:44.
- 977 145. Huizing M, Rakocevic G, Sparks SE, Mamali I, Shatunov A, Goldfarb L, et al.
978 Hypoglycosylation of alpha-dystroglycan in patients with hereditary IBM due to GNE mutations.
979 *Mol Genet Metab.* 2004;81(3):196-202.

980 146. Wehl CC, Baloh RH, Lee Y, Chou TF, Pittman SK, Lopate G, et al. Targeted sequencing and
981 identification of genetic variants in sporadic inclusion body myositis. *Neuromuscul Disord*.
982 2015;25(4):289-96.

983 147. Krause S, Aleo A, Hinderlich S, Merlini L, Tournev I, Walter MC, et al. GNE protein
984 expression and subcellular distribution are unaltered in HIBM. *Neurology*. 2007;69(7):655-9.

985 148. Penner J, Mantey LR, Elgavish S, Ghaderi D, Cirak S, Berger M, et al. Influence of UDP-
986 GlcNAc 2-epimerase/ManNAc kinase mutant proteins on hereditary inclusion body myopathy.
987 *Biochemistry*. 2006;45(9):2968-77.

988 149. Deconinck N, Richard P, Allamand V, Behin A, Lafôret P, Ferreiro A, et al. Bethlem
989 myopathy: long-term follow-up identifies COL6 mutations predicting severe clinical evolution. *J*
990 *Neurol Neurosurg Psychiatry*. 2015;86(12):1337-46.

991 150. Deconinck N, Dion E, Ben Yaou R, Ferreiro A, Eymard B, Briñas L, et al. Differentiating
992 Emery-Dreifuss muscular dystrophy and collagen VI-related myopathies using a specific CT scanner
993 pattern. *Neuromuscul Disord*. 2010;20(8):517-23.

994 151. Martoni E, Urciuolo A, Sabatelli P, Fabris M, Bovolenta M, Neri M, et al. Identification and
995 characterization of novel collagen VI non-canonical splicing mutations causing Ullrich congenital
996 muscular dystrophy. *Hum Mutat*. 2009;30(5):E662-72.

997 152. Foley AR, Hu Y, Zou Y, Yang M, Medne L, Leach M, et al. Large genomic deletions: a
998 novel cause of Ullrich congenital muscular dystrophy. *Annals of neurology*. 2011;69(1):206-11.

999 153. Briñas L, Richard P, Quijano-Roy S, Gartioux C, Ledeuil C, Lacène E, et al. Early onset
1000 collagen VI myopathies: Genetic and clinical correlations. *Annals of neurology*. 2010;68(4):511-20.

1001 154. Cui H, Wang J, Zhang C, Wu G, Zhu C, Tang B, et al. Mutation profile of FLNC gene and its
1002 prognostic relevance in patients with hypertrophic cardiomyopathy. *Molecular genetics & genomic*
1003 *medicine*. 2018;6(6):1104-13.

1004


1005

1006

1007

1008

1009 **FIGURES**



1010

1011 **FIGURE 1. Molecular diagnosis with different genetic myopathy subtypes.** Molecular diagnosis
 1012 using exome sequencing has been established in 49% of the patients with the majority having
 1013 pathogenic variants identified in one of the following genes *GNE* (31%), *DYSF* (27%), *CAPN3*
 1014 (19%), indicating that these genes are likely the major contributors to genetic myopathy-like
 1015 phenotype.

1016

1017

1018

1019

1020


1021

1022

1023

1024

1025



1026

1027 **FIGURE 2. Unique pathogenic variants and percent homozygosity identified in major**
 1028 **myopathy genes.** A) Number of unique pathogenic variants identified in major myopathy genes. B)
 1029 The percentage of homozygosity observed in the major myopathy subtypes. Among the 3 major
 1030 myopathy subtypes, 96% of the limb-girdle muscular dystrophy R2 (LGMDR2) patients caused by
 1031 variants in *DYSF* gene were identified with homozygous variants. C) Mutation spectrum of *CAPN3*
 1032 gene: *CAPN3* variants identified in the current study are distributed throughout the gene. There is no
 1033 specific mutation hot spot region but 3 variants are located in exon 10 indicating it as more unstable
 1034 region prone to genetic variation. D) Two common variants in *GNE* gene: The two common variants
 1035 in *GNE* gene were detected in exome sequencing with high confidence and also further confirmed by
 1036 Sanger sequencing. Left side panel indicates the variants confirmation by exome sequencing. Right
 1037 side panel indicates the variants confirmation by Sanger sequencing.

1038

1039

1040

1041

1042

1043

1044



1045

1046 **FIGURE 3. Classical features of common subtypes identified.** GNE myopathy (A to C): Tibialis
1047 anterior (TA) muscle wasting, normal quadriceps and first dorsal interossei (FDI) muscle wasting
1048 identified respectively. Dysferlinopathy (D, E): Gastrocnemius wasting and biceps lump.
1049 Calpainopathy (F, G): Scapular winging and ankle contracture. Sarcoglycanopathy (H): Calf
1050 hypertrophy. Collagenopathy (I to K): Long finger flexor and ankle contractures.

1051

1052

1053

1054

| Patient No | Clinical/Pathological/Functional Evidence for specific Myopathy Subtype and Variant Classification (Clinical Correlation) | Gene | Variant 1 | Pathogenicity (ACMG guidelines + based on clinical/pathological/functional correlation, literature evidence) | ClinVar Classification | Reported in Literature | Variant 2 | Pathogenicity (ACMG guidelines + based on clinical/pathological/functional correlation, literature evidence) | ClinVar Classification | Published Literature Evidence | Gender | CK Level | Muscle weakness |
|------------|--|---------------------|---------------------------------|--|------------------------------|------------------------|---------------------------------|--|--|-------------------------------|--------|----------|-----------------|
| 1/6 | Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior, Hip adductors, iliopsoas, hamstrings and tibialis anterior | CAPN3 (NM_000070.2) | c.1793_1796delAAAC (frameshift) | Likely Pathogenic | Not found | Not found | c.1793_1796delAAAC (frameshift) | Likely Pathogenic | Not found | Not found | M | 3561 | P |
| 7 | Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior, Hip adductors, iliopsoas, hamstrings and tibialis anterior | CAPN3 (NM_000070.2) | c.1319G>A (p.R440Q) | Pathogenic | Pathogenic | (45-48) | c.1343G>T (p.R448L) | Pathogenic | Not found, similar Pathogenic variant at same location (c.1343G>A (p.R448H)) | Not found | F | NA | P+D |
| 8 | Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior, Hip adductors, iliopsoas, hamstrings and tibialis anterior | CAPN3 (NM_000070.2) | c.261_262delCT (frameshift) | Likely Pathogenic | Not found | Not found | c.261_262delCT (frameshift) | Likely Pathogenic | Not found | Not found | M | 2224 | P |
| 12 | Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior, Hip adductors, iliopsoas, hamstrings and tibialis anterior | CAPN3 (NM_000070.2) | c.2051-1G>T | Pathogenic | Pathogenic | (49-52) | c.2338G>C (p.D780H) | Pathogenic | Pathogenic | (51-54) | M | 5200 | P+D |
| 13 | Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior, Hip adductors, iliopsoas, hamstrings and tibialis anterior | CAPN3 (NM_000070.2) | c.1999delG (frameshift) | Likely Pathogenic | Not found | Not found | c.1999delG (frameshift) | Likely Pathogenic | Not found | Not found | F | 1756 | P |
| 14 | Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior, Hip adductors, iliopsoas, hamstrings and tibialis anterior | CAPN3 (NM_000070.2) | c.1298_1299delTG (p.Val433fs) | Pathogenic | Pathogenic/Likely Pathogenic | (53) | c.2050+1G>A | Pathogenic | Pathogenic | (49, 50) | F | 690 | P |
| 15 | Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior, Hip adductors, | CAPN3 (NM_000070.2) | c.802-9G>A | Pathogenic | Pathogenic | (48, 55-58) | c.802-9G>A | Pathogenic | Pathogenic | (48, 55-58) | F | >2000 | P |

Inherited Myopathies in the Indian Subcontinent

| | | | | | | | | | | | | | |
|----|--|---------------------|-------------------------------|------------|-------------------|----------|---------------------|------------|------------|----------|---|------|---------|
| | iliopsoas, hamstrings and tibialis anterior | | | | | | | | | | | | |
| 16 | Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior ,Hip adductors, iliopsoas, hamstrings and tibialis anterior | CAPN3 (NM_000070.2) | c.1319G>A (p.R440Q) | Pathogenic | Pathogenic | (45-48) | c.1319G>A (p.R440Q) | Pathogenic | Pathogenic | (45-48) | F | 7000 | P |
| 18 | Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior ,Hip adductors, iliopsoas, hamstrings and tibialis anterior | CAPN3 (NM_000070.2) | c.1642delC (p.Arg548AlafsX47) | Pathogenic | Likely Pathogenic | (59) | c.2051-1G>T | Pathogenic | Pathogenic | (49-52) | F | 3877 | P |
| 19 | Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior ,Hip adductors, iliopsoas, hamstrings and tibialis anterior | CAPN3 (NM_000070.2) | c.2051-1G>T | Pathogenic | Pathogenic | (49-52) | c.2338G>C (p.D780H) | Pathogenic | Pathogenic | (51-54) | M | 2503 | P |
| 20 | Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior ,Hip adductors, iliopsoas, hamstrings and tibialis anterior | CAPN3 (NM_000070.2) | c.2338G>C (p.D780H) | Pathogenic | Pathogenic | (51-54) | c.2338G>C (p.D780H) | Pathogenic | Pathogenic | (51-54) | M | 2590 | P |
| 21 | Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior ,Hip adductors, iliopsoas, hamstrings and tibialis anterior | CAPN3 (NM_000070.2) | c.2051-1G>T | Pathogenic | Pathogenic | (49-52) | c.2338G>C (p.D780H) | Pathogenic | Pathogenic | (51-54) | F | 3571 | P+AXIAL |
| 22 | Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior ,Hip adductors, iliopsoas, hamstrings and tibialis anterior | CAPN3 (NM_000070.2) | c.2338G>C (p.D780H) | Pathogenic | Pathogenic | (51-54) | c.2338G>C (p.D780H) | Pathogenic | Pathogenic | (51-54) | F | 2029 | P |
| 23 | Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior ,Hip adductors, iliopsoas, hamstrings and tibialis anterior | CAPN3 (NM_000070.2) | c.2050+1G>A | Pathogenic | Pathogenic | (49, 50) | c.2050+1G>A | Pathogenic | Pathogenic | (49, 50) | M | 855 | P |
| 24 | Calpainopathy-specific features: Soleus and Medial | CAPN3 | c.2051-1G>T | Pathogenic | Pathogenic | (49-52) | c.2338G>C (p.D780H) | Pathogenic | Pathogenic | (51-54) | M | 2300 | P |

| | | | | | | | | | | | | | |
|----|--|-------------------------------|--|------------|------------------------------|-----------|--|------------|------------------------------|-------------|---|-------|-----|
| | Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior, Hip adductors, iliopsoas, hamstrings and tibialis anterior | (NM_000070.2) | | | | | | | | | | | |
| 25 | Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior, Hip adductors, iliopsoas, hamstrings and tibialis anterior | <i>CAPN3</i> (NM_000070.2) | c.1296_1299delTG (frameshift) | Pathogenic | Not found | Not found | c.2092C>T (p.R698C) | Pathogenic | Pathogenic | (49, 60-63) | M | 5507 | P+D |
| 26 | Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior, Hip adductors, iliopsoas, hamstrings and tibialis anterior | <i>CAPN3</i> (NM_000070.2) | c.2338G>C (p.D780H) | Pathogenic | Pathogenic | (51-54) | c.2338G>C (p.D780H) | Pathogenic | Pathogenic | (51-54) | M | 1100 | P |
| 27 | Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior, Hip adductors, iliopsoas, hamstrings and tibialis anterior | <i>CAPN3</i> (NM_000070.2) | c.2338G>C (p.D780H) | Pathogenic | Pathogenic | (51-54) | c.2051-1G>T | Pathogenic | Pathogenic | (49-52) | F | 4600 | P |
| 29 | Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior, Hip adductors, iliopsoas, hamstrings and tibialis anterior | <i>CAPN3</i> (NM_000070.2) | c.2338G>C (p.D780H) | Pathogenic | Pathogenic | (51-54) | c.2338G>C (p.D780H) | Pathogenic | Pathogenic | (51-54) | M | 5400 | D |
| 40 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.3137G>A (p.R1046H) | Pathogenic | Pathogenic/Likely Pathogenic | (64-67) | c.3137G>A (p.R1046H) | Pathogenic | Pathogenic/Likely Pathogenic | (64-67) | M | 8795 | P |
| 41 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.3137G>A (p.R1046H) | Pathogenic | Pathogenic/Likely Pathogenic | (64-67) | c.3137G>A (p.R1046H) | Pathogenic | Pathogenic/Likely Pathogenic | (64-67) | M | 13388 | P |
| 43 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, | <i>DYSF</i> (NM_003494.3) | c.4674_4687delAGATCCATCTG TGA (frameshift) | Pathogenic | Not found | Not found | c.4674_4687delAGATCCATCTG TGA (frameshift) | Pathogenic | Not found | Not found | F | 4250 | P |

| | | | | | | | | | | | | | | |
|----|---|---------------------------|--------------------------------|------------|------------------------------|-------------|----------------------|------------|------------------------------|-----------|---|------|-----|--|
| | wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | | | | | | | | | | | | | |
| 44 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.3041A>G (p.Y1014C) | Pathogenic | Pathogenic/Likely Pathogenic | (68, 69) | c.3041A>G (p.Y1014C) | Pathogenic | Pathogenic/Likely Pathogenic | (68, 69) | F | 9065 | P | |
| 45 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.206T>G (p.V69G) | Pathogenic | Likely Pathogenic | Not found | c.206T>G (p.V69G) | Pathogenic | Likely Pathogenic | Not found | M | 3200 | P | |
| 46 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.6124C>T (p.R2042C) | Pathogenic | Pathogenic/Likely Pathogenic | (69-74) | c.6124C>T (p.R2042C) | Pathogenic | Pathogenic/Likely Pathogenic | (69-74) | M | 3707 | P | |
| 47 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.3517dupT (p.Ser1173fs) | Pathogenic | Pathogenic | (65, 75-77) | c.5713C>T (p.R1905X) | Pathogenic | Pathogenic | (78) | M | NA | P+D | |
| 48 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.4060_4062delTCC (p.S1354del) | Pathogenic | VUS | (79) | c.4060_4062delTCC | Pathogenic | VUS | (79) | F | 1760 | P | |
| 49 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.3041A>G (p.Y1014C) | Pathogenic | Pathogenic/Likely Pathogenic | (68, 69) | c.3041A>G (p.Y1014C) | Pathogenic | Pathogenic/Likely Pathogenic | (68, 69) | F | 2174 | P | |
| 50 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.3041A>G (p.Y1014C) | Pathogenic | Pathogenic/Likely Pathogenic | (68, 69) | c.3041A>G (p.Y1014C) | Pathogenic | Pathogenic/Likely Pathogenic | (68, 69) | F | 6390 | P+D | |

Inherited Myopathies in the Indian Subcontinent

| | | | | | | | | | | | | | |
|-----------|---|---------------------------|-----------------------------------|------------|------------------------------|--------------|-----------------------------------|------------|------------------------------|--------------|---|------|---------|
| 51 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.1129C>T (p.R377X) | Pathogenic | Pathogenic/Likely Pathogenic | (80) | c.1129C>T (p.R377X) | Pathogenic | Pathogenic/Likely Pathogenic | (80) | F | 5400 | P |
| 52 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.6124C>T (p.R2042C) | Pathogenic | Pathogenic/Likely Pathogenic | (69-74) | c.6124C>T (p.R2042C) | Pathogenic | Pathogenic/Likely Pathogenic | (69-74) | M | 4670 | D |
| 54 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.3041A>G (p.Y1014C) | Pathogenic | Pathogenic/Likely Pathogenic | (68, 69) | c.3041A>G (p.Y1014C) | Pathogenic | Pathogenic/Likely Pathogenic | (68, 69) | M | 5048 | P |
| 55 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.796_797delCT (p.Leu298fs) | Pathogenic | Pathogenic | (67, 81, 82) | c.796_797delCT (p.Leu298fs) | Pathogenic | Pathogenic | (67, 81, 82) | F | 2679 | P+AXIAL |
| 56 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.3041A>G (p.Y1014C) | Pathogenic | Pathogenic/Likely Pathogenic | (68, 69) | c.3041A>G (p.Y1014C) | Pathogenic | Pathogenic/Likely Pathogenic | (68, 69) | F | 2970 | P |
| 57 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.3137G>A (p.R1046H) | Pathogenic | Pathogenic/Likely Pathogenic | (64-67) | c.3137G>A (p.R1046H) | Pathogenic | Pathogenic/Likely Pathogenic | (64-67) | F | 1911 | D |
| 59 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.5668-824C>T (p.Asp1890Glyfs*47) | Pathogenic | Pathogenic | (83, 84) | c.5668-824C>T (p.Asp1890Glyfs*47) | Pathogenic | Pathogenic | (83, 84) | M | 7865 | P+D |
| 60 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood | <i>DYSF</i> (NM_003494.3) | c.5668-824C>T (p.Asp1890Glyfs*47) | Pathogenic | Pathogenic | (83, 84) | c.5668-824C>T (p.Asp1890Glyfs*47) | Pathogenic | Pathogenic | (83, 84) | M | 5000 | P |

| | | | | | | | | | | | | | | |
|----|---|---------------------------|-----------------------------------|------------|------------------------------|-----------|-----------------------------------|------------|------------------------------|-----------|---|------|------|--|
| | monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | | | | | | | | | | | | | |
| 61 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.206T>G | Pathogenic | Likely Pathogenic | Not found | c.206T>G | Pathogenic | Likely Pathogenic | Not found | M | 2614 | P | |
| 62 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.3137G>A (p.R1046H) | Pathogenic | Pathogenic/Likely Pathogenic | (64-67) | c.3137G>A (p.R1046H) | Pathogenic | Pathogenic/Likely Pathogenic | (64-67) | F | 8000 | P | |
| 63 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.5668-824C>T (p.Asp1890Glyfs*47) | Pathogenic | Pathogenic | (83, 84) | c.5668-824C>T (p.Asp1890Glyfs*47) | Pathogenic | Pathogenic | (83, 84) | F | 3529 | P | |
| 64 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.5668-824C>T (p.Asp1890Glyfs*47) | Pathogenic | Pathogenic | (83, 84) | c.5668-824C>T (p.Asp1890Glyfs*47) | Pathogenic | Pathogenic | (83, 84) | M | 2285 | P5 | |
| 65 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.5668-824C>T (p.Asp1890Glyfs*47) | Pathogenic | Pathogenic | (83, 84) | c.5668-824C>T (p.Asp1890Glyfs*47) | Pathogenic | Pathogenic | (83, 84) | F | 1014 | P+D6 | |
| 66 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.6124C>T (p.R2042C) | Pathogenic | Pathogenic/Likely Pathogenic | (69-74) | c.6124C>T (p.R2042C) | Pathogenic | Pathogenic/Likely Pathogenic | (69-74) | M | 4225 | P+D | |
| 67 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip | <i>DYSF</i> (NM_003494.3) | c.3137G>A (p.R1046H) | Pathogenic | Pathogenic/Likely Pathogenic | (64-67) | c.3137G>A (p.R1046H) | Pathogenic | Pathogenic/Likely Pathogenic | (64-67) | M | 2000 | P+D0 | |

| | | | | | | | | | | | | | |
|----|---|-----------------------------|----------------------|-------------------|--|-------------|----------------------|-------------------|------------------------------|--------------|---|-------|-----|
| | adductors, hamstrings and quadriceps | | | | | | | | | | | | |
| 68 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.3280T>C (p.W1094R) | Likely Pathogenic | Not found | (85) | c.3280T>C (p.W1094R) | Likely Pathogenic | Not found | (85) | M | 1018 | P |
| 69 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.3041A>G (p.Y1014C) | Pathogenic | Pathogenic/Likely Pathogenic | (68, 69) | c.3041A>G (p.Y1014C) | Pathogenic | Pathogenic/Likely Pathogenic | (68, 69) | M | 26740 | P |
| 74 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.2179G>A (p.V727M) | Pathogenic | Likely Benign/Likely Pathogenic/Pathogenic | (1, 86-88) | c.1664C>T (p.A524V) | Pathogenic | Pathogenic/Likely Pathogenic | (28, 30, 86) | F | 220 | D+P |
| 75 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.1853T>C (p.I587T) | Pathogenic | Pathogenic/Likely Pathogenic | (29, 89-91) | c.1853T>C (p.I587T) | Pathogenic | Pathogenic/Likely Pathogenic | (29, 89-91) | M | 1309 | D+P |
| 76 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | c.1853T>C (p.I587T) | Pathogenic | Pathogenic/Likely Pathogenic | (29, 89-91) | M | 321 | D |
| 78 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | c.1664C>T (p.A524V) | Pathogenic | Pathogenic/Likely Pathogenic | (28, 30, 86) | M | 1334 | D+P |
| 80 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | c.986T>C (p.I298T) | Pathogenic | Likely Pathogenic | (89, 91, 92) | F | 809 | D+P |
| 82 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | c.1664C>T (p.A524V) | Pathogenic | Pathogenic/Likely Pathogenic | (28, 30, 86) | M | 391 | D+P |

Inherited Myopathies in the Indian Subcontinent

| | | | | | | | | | | | | | |
|-----------|---|-----------------------------|---------------------|------------|------------------------------|---------------------|--|------------|------------------------------|---------------------|---|------|-----|
| 84 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachii and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | c.478C>T (p.R160X) | Pathogenic | Likely Pathogenic | (29, 93) | M | 408 | D+P |
| 85 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachii and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.1853T>C (p.I587T) | Pathogenic | Pathogenic/Likely Pathogenic | (29, 89-91) | c.1853T>C (p.I587T) | Pathogenic | Pathogenic/Likely Pathogenic | (29, 89-91) | M | 587 | D+P |
| 86 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachii and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.830G>A (p.R246Q) | Pathogenic | Likely Pathogenic | (28, 89, 91, 94-96) | c.830G>A (p.R246Q) | Pathogenic | Likely Pathogenic | (28, 89, 91, 94-96) | F | 384 | D+P |
| 87 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachii and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | c.986T>C (p.I298T) | Pathogenic | Likely Pathogenic | (89, 91, 92) | F | 242 | D+P |
| 88 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachii and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.1853T>C (p.I587T) | Pathogenic | Pathogenic/Likely Pathogenic | (29, 89-91) | c.1853T>C (p.I587T) | Pathogenic | Pathogenic/Likely Pathogenic | (29, 89-91) | M | 1986 | D+P |
| 89 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachii and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | c.397_398dupAT (p.Glu134fs) (frameshift) | Pathogenic | Pathogenic | Not found | F | 245 | D+P |
| 90 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachii and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | c.1853T>C (p.I587T) | Pathogenic | Pathogenic/Likely Pathogenic | (29, 89-91) | F | 209 | D+P |
| 91 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachii and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | c.1853T>C (p.I587T) | Pathogenic | Pathogenic/Likely Pathogenic | (29, 89-91) | M | 391 | D+P |
| 92 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis | <i>GNE</i> (NM_001128227.3) | c.1853T>C (p.I587T) | Pathogenic | Pathogenic/Likely Pathogenic | (29, 89-91) | c.1853T>C (p.I587T) | Pathogenic | Pathogenic/Likely Pathogenic | (29, 89-91) | F | 102 | D+P |

| | | | | | | | | | | | | | | |
|-----|---|-----------------------------|---------------------|------------|------------------------------|-------------|--------------------------------|-------------------|------------------------------|--------------|---|-----|--|-----|
| | anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachii and first dorsal interosseous muscles | | | | | | | | | | | | | |
| 93 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachii and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | c.2189C>T (p.S699L) | Likely Pathogenic | VUS | (97) | F | 204 | | |
| | | | | | | | | | | | | | | D+P |
| 94 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachii and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | F | 144 | | |
| | | | | | | | | | | | | | | D+P |
| 95 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachii and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.1853T>C (p.I587T) | Pathogenic | Pathogenic/Likely Pathogenic | (29, 89-91) | c.1853T>C (p.I587T) | Pathogenic | Pathogenic/Likely Pathogenic | (29, 89-91) | M | 486 | | |
| | | | | | | | | | | | | | | D+P |
| 96 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachii and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | F | 221 | | |
| | | | | | | | | | | | | | | D+P |
| 97 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachii and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.1853T>C (p.I587T) | Pathogenic | Pathogenic/Likely Pathogenic | (29, 89-91) | c.1853T>C (p.I587T) | Pathogenic | Pathogenic/Likely Pathogenic | (29, 89-91) | M | 152 | | |
| | | | | | | | | | | | | | | D+P |
| 98 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachii and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.478C>T (p.R160X) | Pathogenic | Likely Pathogenic | (29, 93) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | F | 304 | | |
| | | | | | | | | | | | | | | D+P |
| 99 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachii and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | c.816_820delCTCAT (frameshift) | Likely Pathogenic | Not found | Not found | M | 367 | | D+P |
| | | | | | | | | | | | | | | |
| 100 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachii and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | c.1664C>T (p.A524V) | Pathogenic | Pathogenic/Likely Pathogenic | (28, 30, 86) | F | 120 | | D+P |

Inherited Myopathies in the Indian Subcontinent

| | | | | | | | | | | | | | |
|-----|---|-----------------------------|-------------------------------------|-------------------|------------------------------|-------------|---------------------|------------|------------------------------|-------------|---|-----|-----|
| 101 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachii and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | c.1853T>C (p.I587T) | Pathogenic | Pathogenic/Likely Pathogenic | (29, 89-91) | F | 598 | D+P |
| 102 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachii and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | c.1853T>C (p.I587T) | Pathogenic | Pathogenic/Likely Pathogenic | (29, 89-91) | M | 431 | D+P |
| 103 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachii and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | F | 287 | D+P |
| 104 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachii and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | c.268C>T (p.R90X) | Pathogenic | Pathogenic | Not found | M | 293 | D+P |
| 105 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachii and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.97G>T (p.E33X) | Pathogenic | Pathogenic/Likely Pathogenic | Not found | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | F | 307 | D+P |
| 106 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachii and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.925_927delinsTTGGGAT (frameshift) | Likely Pathogenic | Not found | Not found | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | F | 282 | D+P |
| 107 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachii and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.816_820delCTCAT (frameshift) | Likely Pathogenic | Not found | Not found | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | M | 540 | D+P |
| 108 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachii and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.1853T>C (p.I587T) | Pathogenic | Pathogenic/Likely Pathogenic | (29, 89-91) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | F | 207 | D+P |

1056

1057 **P:** Proximal muscles; **D:** Distal muscles; **M:** Male; **F:** Female

1058

1059

1060

1061

1062

1063

1064

1065

1066

1067 **Table 2: Clinical features of common subtypes**

| Parameters | Dysferlinopathy (LGMDR2) | Calpainopathy (LGMDR1) | GNE-myopathy |
|-------------------------------|--|---|---|
| Number of patients | 27 | 19 | 31 |
| Mean age of onset(Range) | 22years (13-33) | 21 years (6 to 48) | 28 years (16-60) |
| Sex ratio (M:F) | 1.25:1 | 1.1:1 | 1.2:1 |
| Duration of illness(Range) | 1-17 years | 1-27 years | 3Months -30years |
| Commonest Presenting symptom | Difficulty running, change in gait | Toe walking, difficulty climbing stairs and getting up from ground | Tripping on small objects |
| Important Clinical markers | Wasting of calves (74%), Biceps lump (45%) | Winging of scapula (83%)and tendo-achilis contractures (71%) | Foot drop and sparing of quadriceps (100%). |
| Muscles most affected | Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | Serratus anterior ,Hip adductors, iliopsoas, hamstrings and tibialis anterior | Tibialis anterior, iliopsoas,adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles |
| Uncommon or Atypical features | Scapular winging and facial weakness (10%) | Diamond on quadriceps , biceps lump and facial weakness. | Scapular winging (6%) |
| Asymmetry at onset | 3% | - | 37% |
| CPK levels(Range) | 1018-26,740 IU/L | 690 to 7000 IU/L | 102-1986 IU/L. |

1068

1069

1070

1071

1072

1073

1074

1075

1076

1077

1078

1079

1080

1081

1082

1083

1084

1085

1086

1087

1088

1089

1090

1091

1092

1093

1094

1095

1096

1097

1098

1099

1100

1101

1102

1103

1104

1105

1106

1107

1108 Table 3. Uncommon subtypes identified in Indian patients.

| Patient No | Clinical/Pathological/Functional Evidence for specific Myopathy Subtype and Variant Classification (Clinical Correlation) | Gene | Variant 1 | Pathogenicity (ACMG guidelines + based on clinical/pathological/functional correlation, literature evidence) | ClinVar Classification | Reported in Published Literature | Variant 2 | Pathogenicity (ACMG guidelines + based on clinical/pathological/functional correlation, literature evidence) | ClinVar Classification | Reported in Published Literature | Gender | CK Level | Muscle weakness |
|------------|---|-----------------------------|---------------------------------|--|--------------------------------|----------------------------------|---------------------------------|--|------------------------|----------------------------------|--------|----------|-----------------|
| 1/6 | Most prominent clinical marker: LGMD variable features: mild to severe (wheelchair-bound) of both proximal and distal muscles, and dilated cardiomyopathy | <i>AMPD1</i> (NM_000036.2) | c.242C>T (p.P81L) | Likely Pathogenic | Likely Benign/Pseudodeficiency | (98) | c.133C>T (p.Q45X) | Pathogenic | VUS | (98, 99) | M | 73 | P+D |
| 2 | Most prominent clinical marker: LGMD variable features: mild to severe (wheelchair-bound) of both proximal and distal muscles, and dilated cardiomyopathy | <i>AMPD1</i> (NM_000036.2) | c.959A>T (p.K320I) | Likely Pathogenic | Likely Pathogenic/VUS | Not found | c.104delC (p.Pro35Leufs*87) | Likely Pathogenic | Benign | (100) | M | 665 | P |
| 3 | Anoctaminopathy-features: Long periods of Myalgias and difficulty running; Important clinical marker: Asymmetric wasting of calves; Most-affected muscles: Gastrocnemius | <i>ANO5</i> (NM_213599.2) | c.1406G>A (p.W469X) | Pathogenic | Pathogenic | Not found | c.1406G>A (p.W469X) | Pathogenic | Pathogenic | Not found | M | 4100 | D |
| 4 | Anoctaminopathy-features: Long periods of Myalgias and difficulty running; Important clinical marker: Asymmetric wasting of calves; Most-affected muscles: Gastrocnemius | <i>ANO5</i> (NM_213599.2) | c.2141_2144dupCTCA (frameshift) | Likely Pathogenic | Not found | Not found | c.2141_2144dupCTCA (frameshift) | Likely Pathogenic | Not found | Not found | M | 1626 | D |
| 5 | Anoctaminopathy-features: Long periods of Myalgias and difficulty running; Important clinical marker: Asymmetric wasting of calves; Most-affected muscles: Gastrocnemius | <i>ANO5</i> (NM_213599.2) | c.1406G>A (p.W469X) | Pathogenic | Pathogenic | Not found | c.1406G>A (p.W469X) | Pathogenic | Pathogenic | Not found | M | 4000 | D |
| 31 | Collagenopathy features: Vastus lateralis muscle MRI showing "sandwich" sign; Difficulty getting up from ground and toe walking; Important clinical marker: Finger flexors and tendo-achillis contractures; Most-affected muscles: Hip extensors and adductors, ankle dorsiflexors. | <i>COL6A1</i> (NM_001848.2) | c.2821_2833del (frameshift) | Likely Pathogenic | Not found | Not found | c.2821_2833del (frameshift) | Likely Pathogenic | Not found | Not found | M | 1056 | P |
| 32 | Collagenopathy features: Vastus lateralis muscle MRI showing "sandwich" sign; Difficulty getting up from ground and toe walking; Important clinical marker: Finger flexors and tendo-achillis contractures; Most-affected muscles: Hip extensors and adductors, ankle dorsiflexors. | <i>COL6A1</i> (NM_001848.2) | c.1056+1G>A | Pathogenic | Pathogenic | (101-105) | - | | | | M | 212 | P |
| 35 | Collagenopathy features: Vastus lateralis muscle MRI showing "sandwich" sign; Difficulty getting up from ground and toe walking; Important clinical marker: Finger flexors and tendo-achillis contractures; Most-affected muscles: Hip extensors and adductors, ankle dorsiflexors. | <i>COL6A2</i> (NM_001849.3) | c.857G>A (G286E) | Pathogenic | Pathogenic/Likely Pathogenic | (106-109) | - | | | | M | 152 | P+D |
| 71 | Emery-Dreifuss muscular-dystrophy features: Tripping and toe walking, Winging of scapula, wrist and ankle contractures; Most-affected muscles: Biceps brachii, ankle dorsiflexors | <i>EMD</i> (NM_000117.2) | c.680delG (frameshift) | Likely Pathogenic | Not found | Not found | - | | | | M | 791 | P |
| 72 | Later-Onset Pompe Disease (LOPD) features: Difficulty getting up from ground followed by breathing difficulty, Respiratory muscles weakness; Most-affected muscles: Hip extensors and respiratory muscles | <i>GAA</i> (NM_000152.5) | c.1A>G (p.M1V) | Pathogenic | Pathogenic/Likely Pathogenic | (110-116) | c.1831G>A (p.G611S) | Likely Pathogenic | VUS | (114, 117, 118) | F | 1197 | P+D |
| 73 | Later-Onset Pompe Disease (LOPD) features: Difficulty getting up from ground followed by breathing difficulty, Respiratory muscles weakness; Most-affected muscles: Hip extensors and respiratory muscles | <i>GAA</i> (NM_000152.5) | c.1841C>T (p.T614M) | Likely Pathogenic | VUS | (12, 119-121) | c.1841C>T (p.T614M) | Likely Pathogenic | VUS | (12, 119-121) | M | 1141 | P |
| 109 | Merosin-deficiency-congenital-muscular-dystrophy-type 1 features: Difficulty getting up from ground; Winging of scapula, calf hypertrophy; Mild upper and lower girdle weakness. | <i>LAMA2</i> (NM_000426.3) | c.2749+1G>C | Pathogenic | Pathogenic | (122-124) | c.2749+1G>C | Pathogenic | Pathogenic | (122-124) | M | 9083 | P |

Inherited Myopathies in the Indian Subcontinent

| | | | | | | | | | | | | | |
|-----|--|--------------------------------|---------------------------|-------------------|------------------------------|------------|---------------------------|---------------------|-------------------|------------|------|-------|-----|
| 37 | Laminopathy features: Difficulty getting up from ground; Muscles most affected: Iliopsoas, hip adductors, hamstrings and quadriceps | <i>LMNA</i> (NM_170707.4) | c.1621C>T (p.R541C) | Pathogenic | Pathogenic/Likely Pathogenic | (125-132) | - | | | F | 1234 | P | |
| 38 | Laminopathy features: Difficulty getting up from ground; Muscles most affected: Iliopsoas, hip adductors, hamstrings and quadriceps. Cardiac involvement: Atrioventricular conduction blocks. | <i>LMNA</i> (NM_170707.4) | c.116A>G (p.N39S) | Pathogenic | Pathogenic | (133-136) | - | | | F | - | P | |
| 39 | Laminopathy features: Difficulty getting up from ground; Muscles most affected: Iliopsoas, hip adductors, hamstrings and quadriceps | <i>LMNA</i> (NM_170707.3) | c.116A>AG (p.N39S) | Pathogenic | Pathogenic | (133-136) | - | | | M | 91 | P | |
| 110 | POMT1-proteinopathy-features: Difficulty getting up from ground, Winging of scapula, calf hypertrophy; Most-affected muscle-weakness: Mild upper and lower girdle weakness | <i>POMT1</i> (NM_007171.3) | c.1868G>C (p.R623T) | Pathogenic | Not found | (137) | c.1868G>C (p.R623T) | Pathogenic | Not found | (137) | F | 2261 | P |
| 111 | Sarcoglycanopathy features: Absent alpha sarcoglycan stain in muscle biopsy immunohistochemistry (IHC); Difficulty getting up from ground and climbing stairs, Calf hypertrophy; Most-affected muscles: Hip and knee extensors, ankle dorsiflexors | <i>SGCA</i> (NM_000023.4) | c.157+1G>A | Pathogenic | Likely Pathogenic | (138, 139) | c.157+1G>A | Pathogenic | Likely Pathogenic | (138, 139) | F | - | P |
| 112 | Sarcoglycanopathy features: Absent beta sarcoglycan stain in muscle biopsy immunohistochemistry (IHC); Difficulty getting up from ground and climbing stairs, Calf hypertrophy; Most-affected muscles: Hip and knee extensors, ankle dorsiflexors | <i>SGCB</i> (NM_000232.4) | c.346A>G (p.M116V) | Likely Pathogenic | VUS | (6) | c.346A>G (p.M116V) | Likely Pathogenic | VUS | (6) | M | 7646 | P |
| 114 | Sarcoglycanopathy features: Absent beta sarcoglycan stain in muscle biopsy immunohistochemistry (IHC); Difficulty getting up from ground and climbing stairs, Calf hypertrophy; Most-affected muscles: Hip and knee extensors, ankle dorsiflexors | <i>SGCB</i> (NM_000232.4) | c.544A>C (p.T182P) | Likely Pathogenic | VUS | (140) | c.544A>C (p.T182P) | Likely Pathogenic | VUS | (140) | F | 15573 | P |
| 124 | Sarcoglycanopathy features: Absent beta sarcoglycan stain in muscle biopsy immunohistochemistry (IHC); Difficulty getting up from ground and climbing stairs, Calf hypertrophy; Most-affected muscles: Hip and knee extensors, ankle dorsiflexors | <i>SGCD</i> (NM_000337.5) | c.493C>T (p. R165X) | Pathogenic | Pathogenic | (141, 142) | c.493C>T | c.493C>T (p. R165X) | Pathogenic | Pathogenic | F | 8224 | P+D |
| 116 | Sarcoglycanopathy features: Absent gamma sarcoglycan stain in muscle biopsy immunohistochemistry (IHC); Difficulty getting up from ground and climbing stairs, Calf hypertrophy; Most-affected muscles: Hip and knee extensors, ankle dorsiflexors | <i>SGCG</i> (NM_000231.2) | c.92G>A (p.W31X) | Likely Pathogenic | Not found | Not found | c.92G>A (p.W31X) | Likely Pathogenic | Not found | Not found | F | 13500 | P+D |
| 118 | Myotilinopathy features: Difficulty getting up from ground, Winging of scapula; Most-affected muscles: Severe upper and lower girdle weakness | <i>MYOT</i> (NM_006790.2) | c.1423C>T (p.Q475X) | Likely Pathogenic | Not found | Not found | - | | | M | - | P | |
| 121 | Telethoninopathy features: Tripping on small objects, Foot-drop with weak quadriceps and scapular-winging; Most-affected muscles: Knee extensors and ankle dorsiflexors | <i>TCAP</i> (NM_003673.3) | c.14_15delAG (frameshift) | Likely Pathogenic | Not found | Not found | c.14_15delAG (frameshift) | Likely Pathogenic | Not found | Not found | M | 619 | P |
| 122 | Telethoninopathy features: Tripping on small objects, Foot-drop with weak quadriceps and scapular-winging; Most-affected muscles: Knee extensors and ankle dorsiflexors | <i>TCAP</i> (NM_003673.3) | c.244C>T (p.Gln82X) | Likely Pathogenic | Not found | (143) | c.244C>T (p.Gln82X) | Likely Pathogenic | Not found | (143) | F | 854 | D |
| 123 | LGMDD1 DNAJB6-related / HSP40-proteinopathy features: Difficulty getting up from ground; Difficulty walking on heels; Muscle most-affected: Hip | <i>DNAJB6</i> (NM_058246.4) | c.273C>G (p.F91L) | Pathogenic | Pathogenic | (144) | - | | | F | 392 | P+D | |

adductors, iliopsoas, gluteus maximus and gastrocnemius

1109
 1110 **P:** Proximal muscles; **D:** Distal muscles; **M:** Male; **F:** Female
 1111
 1112
 1113
 1114
 1115
 1116
 1117
 1118
 1119
 1120 **Table 4: Clinical features of uncommon subtypes**

| Parameters | LGMDR3-R6 (Sarcoglycanopathy) | Collagenopathy(LGMD R22 or LGMD D5; COL6A1/A2/A3) | LGMDR12 (Anoctaminopathy) | LGMDR7 (Telethoninopathy) | Pompe Disease | EDMD2 (LMNA-Laminopathy) | MMDD (AMPD1-Myopathy due to monoadenylate deaminase deficiency) | Myofibrillar Myopathy (MYOT-myotilinopathy) | LGMD11 (DNAJB6, HSP40-proteinopathy) | EDMD1 (EMD-Emery-Dreifuss muscular-dystrophy-X-linked) | LGMDR11 (POMT1-proteinopathy). | LGMD R23 or MDC1A (LAMA2: Merosin-deficiency-congenital-muscular-dystrophy-type 1) |
|--------------------------------|--|--|---|--|--|---|---|---|---|--|--------------------------------------|--|
| Number of patients | 7 | 7 | 3 | 2 | 2 | 3 | 2 | 1 | 1 | 1 | 1 | 1 |
| Most Common Presenting symptom | Difficulty getting up from ground and climbing stairs. | Difficulty getting up from ground and toe walking. | Long periods of Myalgias and difficulty running | Tripping on small objects | Difficulty getting up from ground followed by breathing difficulty | Difficulty getting up from ground | Heterogeneous, LGMD features of mild to severe (wheelchair-bound) of both proximal and distal muscles | Difficulty getting up from ground | Difficulty getting up from ground | Tripping and toe walking | Difficulty getting up from ground | Difficulty getting up from ground |
| Muscles most affected | Hip and knee extensors, ankle dorsiflexors | Hip extensors and adductors,ankle dorsiflexors | Gastrocnemius | Knee extensors and ankle dorsiflexors | Hip extensors and respiratory muscles | Iliopsoas, hip adductors, hamstrings and quadriceps | Both proximal and distal muscle, presentation very heterogeneous | Severe upper and lower girdle weakness | Hip adductors, iliopsoas, gluteus maximus and gastrocnemius | Biceps brachii, ankle dorsiflexors | Mild upper and lower girdle weakness | Mild upper and lower girdle weakness |
| Important clinical markers | Calf hypertrophy | Finger flexors and tendo-achilis contractures | Asymmetric wasting of calves | Foot-drop with weak quadriceps and scapular-winging. | Respiratory - muscles weakness | | LGMD variable features, dilated cardiomyopathy | Winging of scapula | Difficulty walking on heels | Winging of scapula, wrist and ankle contractures | Winging of scapula, calf hypertrophy | Winging of scapula, calf hypertrophy |
| CPK levels(Range) | 6800-15573 IU/L | 152-5467 IU/L. | 1626-4100 IU/L | 854 and 619 IU/L | 1141 and 1197 IU/L | 91-1234U/L | 73 IU/L (normal) to 665 IU/L (mild elevation) | 1100 IU/L | 392 IU/L | 791 IU/L | 2261 IU/L | 9083 IU/L |

1121
 1122
 1123
 1124
 1125
 1126
 1127
 1128
 1129
 1130
 1131
 1132
 1133
 1134
 1135 **Table 5: Clinical symptoms and genotype of patients with pathogenic variants in more than one gene.**

| Patient No. | Gender | Gene | Variant | Zygoty | Classification | CK Level (IU/L) | Muscle Weakness: Proximal (P)/Distal (D) | Muscle Biopsy Result | Ambulation Status (a= ambulatory) | Cardiac Involvement |
|-------------|--------|-------------|---------------------|--------------|-------------------|-----------------|--|----------------------|-----------------------------------|---------------------|
| 118 | Male | <i>GNE</i> | c.2179G>A (p.V727M) | Heterozygous | Pathogenic | NA | P+D | NA | a | No |
| | | <i>GNE</i> | c.827T>G (p.F276C) | Heterozygous | Likely Pathogenic | | | | | |
| | | <i>MYOT</i> | c.1423C>T (p.Q475X) | Heterozygous | Pathogenic | | | | | |
| 42 | Female | <i>DYSF</i> | c.206T>G (p.V69G) | Heterozygous | Pathogenic | 10500 | P | myopathy | a | No |

| | | | | | | | | | | | | | |
|--------|--------|---------------|-----------------------------------|--------------|-------------------|-----------|-----|-------------------------------|---|-----|--|--|------|
| | | <i>DYSF</i> | c.1397+2_1397+3insT | Heterozygous | Likely Pathogenic | | | | | | | | 1136 |
| | | <i>SIL1</i> | c.274C>T (p.R92W) | Heterozygous | Benign | | | | | | | | 1137 |
| | | <i>GAA</i> | c.2725G>A (p.V909M) | Heterozygous | VUS | | | | | | | | 1138 |
| | | <i>GNE</i> | c.2179G>A (p.V727M) | Heterozygous | Pathogenic | | | | | | | | 1139 |
| | | <i>GNE</i> | c.986T>C (p.I298T) | Heterozygous | Pathogenic | | | | | | | | 1140 |
| | | <i>LAMA2</i> | c.5074G>C (p.V1692L) | Heterozygous | VUS | | | | | | | | 1141 |
| | | <i>PLEC</i> | c.5796G>C (p.E1932D) | Heterozygous | VUS | | | | | | | | 1142 |
| 110 | Female | <i>POMT1</i> | c.1868G>C (p.R623T) | Homozygous | Pathogenic | 2261 | P | myopathy | a | No | | | 1143 |
| | | <i>CAPN3</i> | c.1099G>A (p.G367S) | Heterozygous | Pathogenic | | | | | | | | 1144 |
| 85 | Male | <i>CHAT</i> | c.2222G>A (p.R741K) | Heterozygous | VUS | 587 | P | myopathy (left TA affected) | a | No | | | 1145 |
| | | <i>CHRNA2</i> | c.753_754delCT (FS) | Heterozygous | Likely Pathogenic | | | | | | | | 1146 |
| | | <i>DES</i> | c.897+4_897+5delGG | Heterozygous | VUS | | | | | | | | 1147 |
| | | <i>GNE</i> | c.1853T>C (p.I587T) | Homozygous | Pathogenic | | | | | | | | 1148 |
| | | <i>NEB</i> | c.14986G>A (p.G4996R) | Heterozygous | VUS | | | | | | | | 1149 |
| | | <i>PLEC</i> | c.5524C>T (p.R1842W) | Heterozygous | VUS | | | | | | | | 1150 |
| 71 | Male | <i>EMD</i> | c.680delG (FS) | Hemizygous | Likely Pathogenic | 791 | P | NA | a | No | | | 1151 |
| | | <i>PLEC</i> | c.5447_5459delTTGGAGGCCGAGGC (FS) | Heterozygous | Likely Pathogenic | | | | | | | | 1152 |
| | | <i>MYH2</i> | c.3622G>A (p.E1208K) | Heterozygous | VUS | | | | | | | | 1153 |
| 112 | Male | <i>FKRP</i> | c.493C>T (p.P165S) | Heterozygous | VUS | 7646 | P | NA | a | No | | | 1154 |
| | | <i>GAA</i> | c.794G>A (p.S265N) | Heterozygous | Likely Pathogenic | | | | | | | | 1155 |
| | | <i>SGCB</i> | c.346A>G (p.M116V) | Homozygous | Likely Pathogenic | | | | | | | | 1156 |
| | | <i>SGCD</i> | c.68A>G (p.Y23C) | Heterozygous | VUS | | | | | | | | 1157 |
| | | <i>AMPD1</i> | c.317A>G (p.K106R) | Heterozygous | VUS | | | | | | | | 1158 |
| 1 or 6 | Male | <i>CAPN3</i> | c.1793_1796delAAAC (FS) | Homozygous | Likely Pathogenic | 3561 | P | no diagnosis | a | No | | | 1159 |
| | | <i>AMPD1</i> | c.242C>T (p.P81L) | Heterozygous | Likely Pathogenic | | | | | | | | 1160 |
| | | <i>AMPD1</i> | c.133C>T (p.Q45X) | Heterozygous | Pathogenic | | | | | | | | 1161 |
| 39 | Male | <i>DOK7</i> | c.601C>T (p.R201X) | Heterozygous | Pathogenic | 91 | P | NA | a | No | | | 1162 |
| | | <i>DMD</i> | c.932A>G (p.D311G) | Heterozygous | VUS | | | | | | | | 1163 |
| | | <i>LMNA</i> | c.116A>G (p.N39S) | Heterozygous | Pathogenic | | | | | | | | 1164 |
| 47 | Male | <i>DYSF</i> | c.5713C>T (p.Arg1905Ter) | Heterozygous | Pathogenic | Not known | P+D | dystrophy + inflammation | a | Yes | | | 1165 |
| | | <i>DYSF</i> | c.3517dupT (p.Ser1173Phefs) | Heterozygous | Pathogenic | | | | | | | | 1166 |
| | | <i>MYH2</i> | c.4537+1G>A | Heterozygous | Pathogenic | | | | | | | | 1167 |
| 50 | Female | <i>DYSF</i> | c.3041A>G (p.Y1014C) | Homozygous | Pathogenic | 6390 | P+D | Absence of Dysferlin staining | a | NA | | | 1168 |
| | | | | | | | | | | | | | 1169 |
| | | | | | | | | | | | | | 1170 |
| | | | | | | | | | | | | | 1171 |
| | | | | | | | | | | | | | 1172 |
| 23 | Male | <i>ANO5</i> | c.1406G>A (p.W469X) | Heterozygous | Pathogenic | | | | | | | | 1173 |
| | | <i>CAPN3</i> | c.2050+1G>A | Homozygous | Pathogenic | 855 | P | NA | a | NA | | | 1174 |
| | | <i>LIMS2</i> | c.893G>A (p.Trp298X) | Homozygous | Pathogenic | | | | | | | | 1175 |
| 64 | Male | | | | | 22855 | P | NA | a | NA | | | 1176 |
| | | <i>DYSF</i> | c.5668-824C>T | Homozygous | Pathogenic | | | | | | | | 1177 |
| | | <i>COL6A3</i> | c.5766delC (FS) | Heterozygous | Pathogenic | | | | | | | | 1178 |
| 125 | Male | <i>GNE</i> | c.2179G>A (p.V727M) | Heterozygous | Pathogenic | 762 | P | NA | a | NA | | | 1179 |
| | | <i>LMNA</i> | c.706delG (p.Glu236fs) | Heterozygous | Pathogenic | | | | | | | | 1180 |
| | | | | | | | | | | | | | 1181 |
| | | | | | | | | | | | | | 1182 |
| | | | | | | | | | | | | | 1183 |

1184

1185

1186

1187

1188

1189

1190

1191

1192

1193

1194

1195

1196

1197

1198

1199

1200

1201

Abbreviations

| | |
|-------------|-----------------------------------|
| FS | Frameshift |
| Ter | Termination of translation |
| VUS | Variant of Uncertain Significance |
| CK | Serum Creatine Kinase |
| P | Proximal muscle weakness |
| D | Distal muscle weakness |
| a | Ambulatory |
| TA | Tibialis anterior muscle |
| IU/L | international units per liter |

Table 6. Molecular and Clinical aspects of patients (not included in diagnostic yield) with Variants of Uncertain Significance (VUSs) or Likely Pathogenic but with Clinical Correlation with Gene of interest

| Patient No | Clinical/Pathological/Functional Evidence for specific Myopathy Subtype and Variant Classification (Clinical Correlation) | Gene | Variant 1 | Pathogenicity (ACMG guidelines + based on clinical/pathological/functional correlation, literature evidence) | ClinVar Classification | Reported in Literature | Variant 2 | Pathogenicity (ACMG guidelines + based on clinical/pathological/functional correlation, literature evidence) | ClinVar Classification | Published Literature Evidence | Gender | CK Level | Muscle weakness |
|------------|---|-------------------------------|-------------------------------|--|------------------------------|------------------------|---------------------|--|------------------------|-------------------------------|--------|----------|-----------------|
| 9 | Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achillis contractures; Most affected muscles: Serratus anterior ,Hip adductors, iliopsoas, hamstrings and tibialis anterior | <i>CAPN3</i> (NM_000070.2) | c.1298_1299delTG (p.Val433fs) | Pathogenic | Pathogenic/Likely Pathogenic | (53) | c.1745+2T>G | VUS/Likely Pathogenic | Not found | Not found | F | 5440 | P+D |
| 10 | Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achillis contractures; Most affected muscles: Serratus anterior ,Hip adductors, iliopsoas, hamstrings and tibialis anterior | <i>CAPN3</i> (NM_000070.2) | c.430C>T (p.L144F) | VUS/Likely Pathogenic | Not found | Not found | c.430C>T (p.L144F) | VUS/Likely Pathogenic | Not found | Not found | F | NA | P |
| 11 | Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achillis contractures; Most affected muscles: Serratus anterior ,Hip adductors, iliopsoas, hamstrings and tibialis anterior | <i>CAPN3</i> (NM_000070.2) | c.439C>T (p.R147X) | Pathogenic | Pathogenic | Not found | c.1543G>A (p.G515R) | VUS/Likely Pathogenic | VUS | Not found | M | 1786 | P |

Inherited Myopathies in the Indian Subcontinent

| | | | | | | | | | | | | | |
|----|--|--------------------------------|-------------------------------|-----------------------|------------------------------|------------|-------------------------------|-----------------------|-----------|-----------|---|-------|-----|
| 17 | Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior ,Hip adductors, iliopsoas, hamstrings and tibialis anterior | <i>CAPN3</i> (NM_000070.2) | c.380-2A>G | VUS/Likely Pathogenic | Not found | Not found | c.380-2A>G | VUS/Likely Pathogenic | Not found | Not found | M | 4686 | P |
| 28 | Calpainopathy-specific features: Soleus and Medial Gastrocnemius muscle MRI showing fatty replacement and atrophy; Toe walking, difficulty climbing stairs and getting up from ground, Winging of scapula and tendo-achilis contractures; Most affected muscles: Serratus anterior ,Hip adductors, iliopsoas, hamstrings and tibialis anterior | <i>CAPN3</i> (NM_000070.2) | c.1347C>A | VUS/Likely Pathogenic | Not found | Not found | c.1347C>A | VUS/Likely Pathogenic | Not found | Not found | F | 4226 | P |
| 42 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.206T>G (p.V69G) | Pathogenic | Likely Pathogenic/VUS | Not found | c.1397+2_1397+3insT | VUS/Likely Pathogenic | VUS | Not found | F | 10500 | P |
| 53 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.4168-1G>A | VUS/Likely Pathogenic | Not found | Not found | c.4168-1G>A | VUS/Likely Pathogenic | Not found | Not found | M | 17503 | D |
| 58 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.3067A>T | VUS/Likely Pathogenic | Not found | Not found | c.4996delC (frameshift) | Likely Pathogenic | Not found | Not found | F | 6476 | P |
| 70 | Dysferlinopathy-specific features: Absent Dysferlin stain in muscle immunohistochemistry (IHC), and disease-range blood monocyte assay for DYSF protein estimation; Difficulty running, change in gait, wasting of calves, biceps lump; Most-affected muscles: Gastrocnemius, Iliopsoas, hip adductors, hamstrings and quadriceps | <i>DYSF</i> (NM_003494.3) | c.2995T>C (W1017R) | VUS/Likely Pathogenic | VUS | Not found | c.2995T>C (W1017R) | VUS/Likely Pathogenic | VUS | Not found | M | 13502 | P+D |
| 77 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | c.1822C>A (p.P577T) | VUS/Likely Pathogenic | VUS | Not found | M | 799 | D+P |
| 79 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | c.95T>C (p.M32T) | VUS/Likely Pathogenic | VUS | Not found | M | 1880 | D+P |
| 81 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.2179G>A (p.V727M) | Pathogenic | Likely Pathogenic/Pathogenic | (1, 86-88) | c.1822C>A (p.P577T) | VUS/Likely Pathogenic | VUS | Not found | F | 210 | D+P |
| 83 | GNE-myopathy-specific features: Rimmed vacuoles in muscle biopsies histochemistry; Tripping on small objects, foot drop and sparing of quadriceps; Most-affected muscles: Tibialis anterior, iliopsoas, adductors of thigh, hamstrings and biceps brachi and first dorsal interosseous muscles | <i>GNE</i> (NM_001128227.3) | c.124C>T (p.R11W) | Pathogenic | Likely Pathogenic | (145-148) | c.827T>G (p.F276C) | VUS/Likely Pathogenic | Not found | Not found | M | 1415 | D+P |
| 30 | Collagenopathy features: Vastus lateralis muscle MRI showing “sandwich” sign; Difficulty getting up from ground and toe walking; Important clinical marker: Finger flexors and tendo-achilis contractures; Most-affected muscles: | <i>COL6A1</i> (NM_001848.2) | c.1848_1850delCCT (p.L617del) | VUS/Likely Pathogenic | VUS | Not found | c.1848_1850delCCT (p.L617del) | VUS/Likely Pathogenic | VUS | Not found | M | 455 | P+D |

Inherited Myopathies in the Indian Subcontinent

| | | | | | | | | | | | | | |
|-----|---|-----------------------------------|---|-------------------------------|-----------|-----------|---|---|------------------------------|-----------|---|------|-----|
| | Hip extensors and adductors, ankle dorsiflexors. | | | | | | | | | | | | |
| 33 | Collagenopathy features: Vastus lateralis muscle MRI showing “sandwich” sign; Difficulty getting up from ground and toe walking; Important clinical marker: Finger flexors and tendo-achillis contractures; Most-affected muscles: Hip extensors and adductors, ankle dorsiflexors. | <i>COL6A2</i> (NM_001849.3) | c.1591G>A (p.G531S) | VUS/Likely Pathogenic | VUS | Not found | c.1970-9G>A | Pathogenic | Pathogenic/Likely Pathogenic | (149-153) | M | 5467 | P |
| 34 | Collagenopathy features: Vastus lateralis muscle MRI showing “sandwich” sign; Difficulty getting up from ground and toe walking; Important clinical marker: Finger flexors and tendo-achillis contractures; Most-affected muscles: Hip extensors and adductors, ankle dorsiflexors. | <i>COL6A2</i> (NM_001849.3) | c.1900G>A (p.E634K) | VUS/Likely Pathogenic | Not found | Not found | c.1970-2A>G | VUS/Likely Pathogenic | Not found | Not found | F | 215 | P |
| 36 | Collagenopathy features: Vastus lateralis muscle MRI showing “sandwich” sign; Difficulty getting up from ground and toe walking; Important clinical marker: Finger flexors and tendo-achillis contractures; Most-affected muscles: Hip extensors and adductors, ankle dorsiflexors. | <i>COL6A3</i> (NM_004369.3) | c.8301_8303delCTT (p.Y2767_F2768del) | VUS/Likely Pathogenic | Not found | Not found | c.8301_8303delCTT (p.Y2767_F2768del) | VUS/Likely Pathogenic | Not found | Not found | F | 615 | P+D |
| 119 | Filaminopathy-features: Difficulty getting up from ground, Winging of scapula; Most-affected muscles: Mild Upper and lower girdle weakness | <i>FLNC</i> (NM_001458.4) | c.5278G>A (p.G1760S) | Likely Pathogenic | VUS | (10, 154) | c.6043G>C (p.V2015L) | VUS/Likely Pathogenic (South Asia MAF: 0.0061%) | Not found | Not found | M | 500 | P |
| 113 | Sarcoglycanopathy features: Absent beta sarcoglycan stain in muscle biopsy immunohistochemistry (IHC); Difficulty getting up from ground and climbing stairs, Calf hypertrophy; Most-affected muscles: Hip and knee extensors, ankle dorsiflexors | <i>SGCB</i> (NM_000232.4) | c.544A>C (p.T182P) | Likely Pathogenic | VUS | (140) | c.181A>G (p.K61E) | VUS/Likely Pathogenic (novel) | Not found | Not found | F | 6800 | P |
| 115 | Sarcoglycanopathy features: Absent beta sarcoglycan stain in muscle biopsy immunohistochemistry (IHC); Difficulty getting up from ground and climbing stairs, Calf hypertrophy; Most-affected muscles: Hip and knee extensors, ankle dorsiflexors | <i>SGCB</i> (NM_000232.4) | c.335A>T | VUS/Likely Pathogenic (novel) | Not found | Not found | c.335A>T | VUS/Likely Pathogenic (novel) | Not found | Not found | F | 7650 | P |
| 117 | TRIM32-proteinopathy features: Difficulty getting up from ground, Calf hypertrophy; Most-affected muscles: Mild upper and lower girdle weakness | <i>TRIM32</i> (NM_001099679.2) | c.59G>T (p.C20F) | VUS/Likely Pathogenic | Not found | Not found | c.59G>T (p.C20F) | VUS/Likely Pathogenic | Not found | Not found | F | 1708 | P+D |

1203

1204

1205

1206

1207

1208

1209

1210

1211

1212

1213

1214

1215

1216

1217

1218

1219

1220

1221

1222

1223

1224

1225